coronary artery disease - myocardial revascularization - all type of patient clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>coronary artery disease</strong> - myocardial revascularization </a> - all type of patient trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="index.html"> RITA 2, 1997 </a> <br> </td> <td> PTCA within 3 mo of the randomisation<br>  <i>versus</i> <br> medical treatment </td> <td> Angina leading to admission within 90days, previous Q wave MI, no previousPTCA, no left main stem disease </td> <td> follow-up 7y<br> n=504/514<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> ACME, 1992 </a> <br> </td> <td> PTCA within 3 days of randomization<br>  <i>versus</i> <br> medical treatment (nitrates, beta-blockers, calcium blockers) </td> <td> Stable angina, history of angina, MIwithin 3 months, exercise test with STdepression >3 mm, no previous PTCA; Single or serial stenosis within sameartery 70% to 99% proximal twothirds </td> <td> follow-up 5y<br> n=105/107<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> Sievers, 1993 </a> <br> </td> <td> PTCA<br>  <i>versus</i> <br> medical treatment </td> <td> Previous nonQ wave MI, no angina indaily life, no previous Q wave MI </td> <td> follow-up 2y<br> n=44/44<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> MASS, 1995 </a> <br> </td> <td> PTCA<br>  <i>versus</i> <br> medical treatment (aspirin, nitrates, beta-blockers and calcium channel blocking </td> <td> Stable angina, no Q wave MI, no leftventricular dysfunction^¾ </td> <td> follow-up 5y<br> n=72/72<br> Parallel groups<br> open <br> Brazil </td> </tr> <tr> <td> <a href="index.html"> BARI, 1996 </a> <br> NCT00000462 </td> <td> PTCA<br>  <i>versus</i> <br> CABG </td> <td> Patients with multivessel disease </td> <td> follow-up 5.4 y<br> n=915/914<br> <br> open <br> USA, Canada </td> </tr> <tr> <td> <a href="index.html"> MASS, 1995 </a> <br> </td> <td> percutaneous transluminal coronaryangioplasty<br>  <i>versus</i> <br> mammary bypass surgery </td> <td> patients with stable angina,normal ventricular function and a proximal stenosis of the leftanterior descending coronary artery >80% </td> <td> follow-up 3.2 y<br> n=72/70<br> <br> open <br> Brazil </td> </tr> <tr> <td> <a href="index.html"> CABRI, 1995 </a> <br> </td> <td> percutaneous transluminal coronary angioplasty<br>  <i>versus</i> <br> coronary artery bypass grafting </td> <td> patients with symptomatic multivessel coronary disease </td> <td> follow-up 1 y<br> n=541/513<br> <br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> EAST, 1994 </a> <br> NCT00000465 </td> <td> transluminal coronary angioplasty<br>  <i>versus</i> <br> coronary-artery bypass grafting </td> <td> patients with multivessels coronary artery disease </td> <td> follow-up 3 y<br> n=198/194<br> <br> open <br> USA </td> </tr> <tr> <td> <a href="index.html"> GABI, 1994 </a> <br> </td> <td> Percutaneous transluminal coronary angioplasty<br>  <i>versus</i> <br> coronary-artery bypass grafting </td> <td> patients with symptomatic multivessel coronary disease </td> <td> follow-up 1 y<br> n=182/177<br> <br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> Lausanne, 1994 </a> <br> </td> <td> transluminal coronary angioplasty<br>  <i>versus</i> <br> Coronary artery bypass grafting </td> <td> patients with isolated proximal left anterior descending artery stenosis, conserved left ventricular function, and documented ischaemia </td> <td> follow-up 3.2 y<br> n=68/66<br> <br> open <br> Switzerland </td> </tr> <tr> <td> <a href="index.html"> RITA, 1993 </a> <br> </td> <td> percutaneous transluminal coronary angioplasty<br>  <i>versus</i> <br> coronary artery bypass surgery </td> <td> patients with one, two, or three diseased coronary arteries </td> <td> follow-up 2.5 y (6.5y)<br> n=510/501<br> <br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> ERACI, 1992 </a> <br> </td> <td> Percutaneous transluminal coronary angioplasty<br>  <i>versus</i> <br> coronary artery bypass grafting </td> <td> patients with multivessel disease and lesions suitable for either form of therapy </td> <td> follow-up 3.8 y<br> n=63/64<br> <br> open <br> Argentina </td> </tr> <tr> <td> <a href="index.html"> Toulouse, 1992 </a> <br> </td> <td> PTCA<br>  <i>versus</i> <br> CABG </td> <td> patients with multivessels coronary artery disease </td> <td> follow-up 2.8 y<br> n=76/76<br> <br> open <br> France </td> </tr> <tr> <td> <a href="index.html"> Serruys Benestent 2, 1998 </a> <br> </td> <td> Heparin-coated Palmaz-Schatz<br>  <i>versus</i> <br> ballon angioplastyaspirin >=100mg 6 month </td> <td> Stable and unstable angina </td> <td> follow-up 12 months<br> n=414/413<br> Parallel groups<br> Open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> Versaci , 1997 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> standard coronary angioplasty, aspirin and diltiazem indefinitely </td> <td> patients with isolated stenosis of the proximal left anterior descending coronary artery </td> <td> follow-up 12 months<br> n=60/60<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> Fischman STRESS, 1994 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> ballon angioplasty aspirin, dipyridamol </td> <td> Stable angina </td> <td> follow-up 6 months<br> n=205/202<br> Parallel groups<br> Open <br> USA </td> </tr> <tr> <td> <a href="index.html"> Serruys Benestent, 1994 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> balloon angioplasty, aspirin 250-500 mg + dipyridamole 75 mgx3 </td> <td> Stable angina </td> <td> follow-up 7 months<br> n=262/258<br> Parallel groups<br> Open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> ACME 2 (Folland), 1997 </a> <br> </td> <td> PTCA <br>  <i>versus</i> <br> medical therapy </td> <td> Stable angina, history of angina, MIwithin 3 months, exercise test with STdepression >3 mm, no previous PTCA; Stenosis >70% proximal two thirds,no main artery stenosis >50%, no 3vessel disease </td> <td> follow-up 5y<br> n=51/50<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> AVERT, 1995 </a> <br> </td> <td> angioplasty<br>  <i>versus</i> <br> atorvastatin at 80 mg per day </td> <td> Angina or asymptomatic, MI orunstable angina but not within 14 days,no triple vessel disease </td> <td> follow-up 1.5y<br> n=177/164<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Moer, 2001 </a> <br> </td> <td> elective stenting treatment with the heparin (Hepamed)-coated beStent<br>  <i>versus</i> <br> PTCA </td> <td> patients with stable or unstable angina </td> <td> follow-up 6 months<br> n=74/71<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Doucet, 2001 </a> <br> </td> <td> stent implantation (beStent-Artist)<br>  <i>versus</i> <br> angioplasty alone </td> <td> symptomatic patients needing dilatation of 1 native coronary vessel between 2.3 and 2.9 mm in size </td> <td> follow-up 6 months<br> n=169/182<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Koning, 2001 </a> <br> </td> <td> stent implantation (beStent Small)<br>  <i>versus</i> <br> standard balloon angioplasty </td> <td> symptomatic patients with de novo focal lesion located on a small coronary segment vessel (<3 mm) </td> <td> follow-up 6 months<br> n=192/189<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Park, 2000 </a> <br> </td> <td> elective stent placement (7-cell NIR stent)<br>  <i>versus</i> <br> balloon angioplasty </td> <td> patients with lesions in small coronary arteries (de novo, non-ostial lesion and reference diameter <3 mm) </td> <td> follow-up 6 months (16 m)<br> n=60/60<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lotan, 2000 </a> <br> </td> <td> stent implantation (AVE Micro Stent)<br>  <i>versus</i> <br> no further treatment </td> <td> with total coronary artery occlusions who had an optimal PTCA result </td> <td> follow-up 6 months<br> n=48/48<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Weaver, 2000 </a> <br> </td> <td> routine stent implantation (Palmaz-Schatz)<br>  <i>versus</i> <br> balloon angioplasty and provisional stenting </td> <td> patients undergoing single-vessel coronary angioplasty </td> <td> follow-up 6 months<br> n=229/248<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Dangas, 2000 </a> <br> </td> <td> elective stenting (Palmaz-Schatz stent)<br>  <i>versus</i> <br> PTCA with prolonged perfusion balloon inflation </td> <td> patients with discrete, de novo lesions in native coronary arteries > or =3 mm in diameter </td> <td> follow-up 8 months<br> n=31/66<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Fluck, 2000 </a> <br> </td> <td> Wiktor stent<br>  <i>versus</i> <br> balloon angioplasty </td> <td> Symptomatic CAD; no AMI in previous 7 d </td> <td> follow-up 12 months<br> n=154/146<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lafont, 2000 </a> <br> </td> <td> systematic stenting<br>  <i>versus</i> <br> provisional stenting (group 1, in which stenting was performed if postangioplasty coronary velocity reserve was <2.2 and/or residual stenosis > or =35% or as bail-out) </td> <td> patients undergoing elective coronary angioplasty </td> <td> follow-up 6 months<br> n=125/126<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Witkowski, 2000 </a> <br> </td> <td> Palmaz-Schatz stent<br>  <i>versus</i> <br> angioplasty </td> <td> Symptomatic CAD; no AMI in previous 14 d </td> <td> follow-up 6 months<br> n=192/196<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Kastrati, 2000 </a> <br> </td> <td> Multilink<br>  <i>versus</i> <br> PTCA </td> <td> Patients with symptomatic coronary artery disease with lesions situated in native coronary vessels between 2 and 2.8 mm in size </td> <td> follow-up 7 months<br> n=204/200<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Di Marlo, 2000 </a> <br> </td> <td> elective stent implantation<br>  <i>versus</i> <br> guided PTCA </td> <td> Stable and unstable angina; no AMI inprevious 24 h </td> <td> follow-up 12 months<br> n=370/365<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Serruys, 2000 </a> <br> </td> <td> primary stenting<br>  <i>versus</i> <br> balloon angioplasty </td> <td> patients scheduled for single-vessel angioplasty </td> <td> follow-up 12 months<br> n=97/511<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Lincoff (EPISTENT), 1999 </a> <br> NCT00271401 </td> <td> stent followed by aspirin 325 mg, abciximab<br>  <i>versus</i> <br> balloon angioplasty followed by aspirin 325 mg, abciximab </td> <td> patients with ischaemic heart disease and suitable coronary-artery lesions </td> <td> follow-up 6 months<br> n=794/796<br> Parallel groups<br> open <br> USA, Canada </td> </tr> <tr> <td> <a href="index.html"> Buller, 1999 </a> <br> </td> <td> Heparin-coated Palmaz-Schatz<br>  <i>versus</i> <br> PTCA </td> <td> patients with nonacute native coronary occlusions </td> <td> follow-up 6 months<br> n=202/208<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Betriu, 1999 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> standard balloon angioplasty </td> <td> Stable and unstable angina </td> <td> follow-up 6 months (4y)<br> n=229/223<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Hoher, 1999 </a> <br> </td> <td> Wiktor<br>  <i>versus</i> <br> PTCA alone </td> <td> patients with a thrombolysis in myocardial infarction grade 0 chronic coronary occlusion </td> <td> follow-up 6 months<br> n=42/43<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Sievert, 1999 </a> <br> </td> <td> stent implantation<br>  <i>versus</i> <br> angioplasty alone </td> <td> Stable angina </td> <td> follow-up 4 months<br> n=55/55<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Eeckout, 1996 </a> <br> </td> <td> Wiktor stent implantation<br>  <i>versus</i> <br> conventional balloon angioplasty </td> <td> Stable angina </td> <td> follow-up 6 months<br> n=42/42<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Sirnes, 1996 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> PTCA alone </td> <td> patients with a satisfactory result after successful recanalization by PTCA of a chronic coronary occlusion </td> <td> follow-up 6 months<br> n=58/59<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Savage, 1998 </a> <br> </td> <td> Palmaz-Schatz stent<br>  <i>versus</i> <br> standard balloon angioplasty </td> <td> patients with new lesions in aortocoronary-venous bypass grafts </td> <td> follow-up 6 months<br> n=108/107<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Erbel, 1998 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> standard balloon angioplasty </td> <td> patients with clinical and angiographic evidence of restenosis after at least one balloon angioplasty </td> <td> follow-up 6 months<br> n=191/192<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Rubartelli, 1998 </a> <br> </td> <td> Palmaz-Schatz stent implantation<br>  <i>versus</i> <br> PTCA alone </td> <td> patients with recanalized total occlusion </td> <td> follow-up 9 months<br> n=56/54<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Hancock, 1998 </a> <br> </td> <td> Palmaz-Schatz<br>  <i>versus</i> <br> angioplasty alone </td> <td> patients with a total coronary occlusion successfully treated by PTCA </td> <td> follow-up 6 months<br> n=30/30<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Rodriguez, 1998 </a> <br> </td> <td> stent<br>  <i>versus</i> <br> optimal PTCA </td> <td> patients obtaining a good immediate angiographic result after percutaneous transluminal coronary angioplasty </td> <td> follow-up 6 months<br> n=57/59<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> COURAGE, 2007 </a> <br> NCT00007657 </td> <td> PCI coupled with optimal medical therapy<br>  <i>versus</i> <br> optimal medical therapy aloneitm </td> <td> patients with stable coronary artery disease </td> <td> follow-up median 4.6 y<br> n=1149/1138<br> Parallel groups<br> open <br> Canada, US </td> </tr> <tr> <td> <a href="index.html"> MASS II, 2007 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> medical therapy </td> <td> patients with multivessel coronary artery disease with stable angina and preserved ventricular function </td> <td> follow-up 5y<br> n=205/203<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> MASS II, 2007 </a> <br> </td> <td> coronary artery bypass graft (CABG)<br>  <i>versus</i> <br> medical therapy </td> <td> multivessel coronary artery disease with stable angina and preserved ventricular function. </td> <td> follow-up 5 years<br> n=203/203<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Tomai, 2008 </a> <br> </td> <td> sirolimus-eluting stent<br>  <i>versus</i> <br> paclitaxel-eluting stent </td> <td> diabetic patient with multiple de novo coronary artery lesions </td> <td> follow-up 8 months<br> n=60/60<br> Cross over<br> NA <br> Italy </td> </tr> <tr> <td> <a href="index.html"> Kochiadakis, 2007 </a> <br> </td> <td> sirolimus-eluting stents<br>  <i>versus</i> <br> bare metal stent </td> <td> one-vesseldisease (>70% narrowing of the lumen of one major epicardialcoronary artery); stable coronary artery disease, age <70 years, and vessel referencediameter >=2.5 mm </td> <td> follow-up 4.8 months (mean)<br> n=38/43<br> Parallel groups<br> open <br> Greece </td> </tr> <tr> <td> <a href="index.html"> RAVEL, 2002 </a> <br> NCT00233805 </td> <td> coated Bx Velocity<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, silent ischaemia; single primary target lesion in a native coronary artery </td> <td> follow-up 12 months<br> n=120/118<br> Parallel groups<br> double-blind <br> Global </td> </tr> <tr> <td> <a href="index.html"> SIRIUS, 2003 </a> <br> NCT00232765 </td> <td> SES<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, signs of myocardial ischaemia </td> <td> follow-up 9 months<br> n=533/525<br> Parallel groups<br> double-blind <br> United States </td> </tr> <tr> <td> <a href="index.html"> C-SIRIUS, 2004 </a> <br> NCT00381420 </td> <td> coated Bx-VELOCITY<br>  <i>versus</i> <br> Bx-VELOCITY </td> <td> Stable or unstable AP, silent ischaemia </td> <td> follow-up 9 months<br> n=50/50<br> Parallel groups<br> double-blind <br> Canada </td> </tr> <tr> <td> <a href="index.html"> E-SIRIUS, 2003 </a> <br> NCT00235144 </td> <td> coated Bx Velocity<br>  <i>versus</i> <br> Bx Velocity </td> <td> Stable or unstable AP, silent ischaemia; single-vessel or multivessel coronary disease but with only one new lesion with an estimated stenosis of more than 50% but less than 100% in a major native coronary artery requiring treatment </td> <td> follow-up 9 months<br> n=175/177<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> TAXUS I, 2003 </a> <br> </td> <td> TAXUS NIR<br>  <i>versus</i> <br> NIR stent </td> <td> Stable or unstable AP, silent ischaemia; single de novo or restenotic coronary lesions </td> <td> follow-up 12 months<br> n=31/30<br> Parallel groups<br> double-blind <br> Germany </td> </tr> <tr> <td> <a href="index.html"> TAXUS II, 2003 </a> <br> NCT00299026 </td> <td> TAXUS<br>  <i>versus</i> <br> NIR stent </td> <td> Stable or unstable AP, silent ischaemia; single de novo target lesion with estimatedstenosis >50% and <99%, </td> <td> follow-up 12 months<br> n=266/270<br> Parallel groups<br> double-blind <br> Global </td> </tr> <tr> <td> <a href="index.html"> TAXUS IV, 2004 </a> <br> NCT00292474 </td> <td> TAXUS<br>  <i>versus</i> <br> EXPRESS </td> <td> Stable or unstable AP, provokable ischaemia with a single, previously untreated coronary-artery stenosis (vessel diameter, 2.5 to 3.75 mm; lesion length, 10 to 28 mm) </td> <td> follow-up 9 months<br> n=662/652<br> Parallel groups<br> double-blind <br> United States </td> </tr> <tr> <td> <a href="index.html"> ASPECT, 2003 </a> <br> NCT00196079 </td> <td> coated Supra-G stent<br>  <i>versus</i> <br> Supra-G stent </td> <td> patientswith discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) </td> <td> follow-up 6 months<br> n=117/58<br> Parallel groups<br> double-blind <br> NA </td> </tr> <tr> <td> <a href="index.html"> ELUTES, 2004 </a> <br> </td> <td> coated V-Flex Plus<br>  <i>versus</i> <br> V-Flex Plus </td> <td> single de novo type A or type B1 lesions 15 mm length in a nativecoronary artery </td> <td> follow-up 12 months<br> n=152/38<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> DELIVER, 2004 </a> <br> </td> <td> non-polymer-based paclitaxel-coated ACHIEVE stent<br>  <i>versus</i> <br> stainless steel Multi-Link (ML) PENTA stent </td> <td> patients with focal de novo coronary lesions, <25 mm in length, in 2.5- to 4.0-mm vessels </td> <td> follow-up 9 months<br> n=524/519<br> Parallel groups<br> single-blind <br> US </td> </tr> <tr> <td> <a href="index.html"> PATENCY, 2002 </a> <br> </td> <td> Logic PTX paclitaxel Eluting CoronaryStents<br>  <i>versus</i> <br> uncoated control stents </td> <td> Patients with de novo lesions of 2.7- to 4.0-mm diameter and 25-mm length received 3.0, 3.5, or 4.0 mm 10- or 15-mm </td> <td> follow-up 9 months<br> n=24/26<br> Parallel groups<br> double blind <br> </td> </tr> <tr> <td> <a href="index.html"> SCORE, 2004 </a> <br> </td> <td> QuaDDS stents (paclitaxel)<br>  <i>versus</i> <br> uncoated control stents </td> <td> patients with focal, de novo coronary lesions </td> <td> follow-up 12 months<br> n=126/140<br> Parallel groups<br> open <br> Worldwide </td> </tr> <tr> <td> <a href="index.html"> ACTION, 2004 </a> <br> </td> <td> Multilink Tetra stent<br>  <i>versus</i> <br> uncoated Multilink Tetra stent </td> <td> Patients with stable angina pectoris orsilent ischemia and a single de novo lesion in a nativecoronary artery >=3.0 mm and <=4.0 mm in diameter thatcould be covered by an 18-mm stent </td> <td> follow-up 6 months<br> n=241/119<br> Parallel groups<br> single-blind <br> worldwide </td> </tr> <tr> <td> <a href="index.html"> FUTURE I, 2004 </a> <br> </td> <td> everolimus coated S-Stent<br>  <i>versus</i> <br> S-Stent </td> <td> de novo coronary lesions </td> <td> follow-up 12 months<br> n=27/15<br> Parallel groups<br> single-blind <br> Germany </td> </tr> <tr> <td> <a href="index.html"> FUTURE II, 2006 </a> <br> </td> <td> CHAMPION<br>  <i>versus</i> <br> bare-metal stent </td> <td> Patients with de novo lesions in vessels with a reference diameter of 2.75-4.0 mm and length  </td><td> follow-up 6 months<br> n=43/21<br> Parallel groups<br> double-blind <br> NA </td> </tr> <tr> <td> <a href="index.html"> TAXUS V (all patients), 2005 </a> <br> NCT00301522 </td> <td> TAXUS<br>  <i>versus</i> <br> bare metal EXPRESS-2 </td> <td> Stable or unstable AP, silent ischaemia with single coronary artery stenosis including complex or previously unstudied lesions (requiring 2.25-mm, 4.0-mm, and/or multiple stents) </td> <td> follow-up 9 months<br> n=577/579<br> Parallel groups<br> double-blind <br> United States </td> </tr> <tr> <td> <a href="index.html"> TAXUS VI, 2005 </a> <br> NCT00297804 </td> <td> TAXUS<br>  <i>versus</i> <br> Express2 stent </td> <td> Stable or unstable AP, silent ischaemia with long, complex coronary artery lesions </td> <td> follow-up 9 months (2y)<br> n=219/227<br> Parallel groups<br> double-blind <br> Europe </td> </tr> <tr> <td> <a href="index.html"> PASSION, 2006 </a> <br> ISRCTN65027270 </td> <td> Taxus Express2<br>  <i>versus</i> <br> Express2 or Liberté </td> <td> Myocardial Infarction with ST-Segment Elevation </td> <td> follow-up 12 months (5y)<br> n=310/309<br> Parallel groups<br> open <br> The Netherlands </td> </tr> <tr> <td> <a href="index.html"> HAAMU-STENT, 2006 </a> <br> </td> <td> Taxus Express<br>  <i>versus</i> <br> Bare-metal-stent </td> <td> AMI - STEMI patients undergoing PCI </td> <td> follow-up 12 months<br> n=70/75<br> Parallel groups<br> open <br> Finland </td> </tr> <tr> <td> <a href="index.html"> SES-SMART, 2004 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Bx Sonic </td> <td> Stable AP, ACS, silent myocardial ischaemia as shown by exercise stress test </td> <td> follow-up 8 months<br> n=129/128<br> Parallel groups<br> single-blind <br> Italian </td> </tr> <tr> <td> <a href="index.html"> DIABETES, 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Bx Velocity/Sonic </td> <td> de novo lesions in native coronary arteriesin 1, 2, or 3 native vessels with symptoms or objective evidence of ischemia; vessel size smaller than 4.0 mm </td> <td> follow-up 9 months<br> n=80/80<br> Parallel groups<br> open <br> Spanish </td> </tr> <tr> <td> <a href="index.html"> Pache et al, 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> BeStent 2 </td> <td> with symptomatic coronary artery disease and significant angiographic stenosis in native coronary vessels </td> <td> follow-up 12 months<br> n=250/250<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> PRISON II, 2006 </a> <br> NCT00258596 </td> <td> Cypher<br>  <i>versus</i> <br> BxVelocity </td> <td> Chronic total occlusion, positive exercise stress test </td> <td> follow-up 6 months<br> n=100/100<br> Parallel groups<br> single-blind <br> Belgium </td> </tr> <tr> <td> <a href="index.html"> SCANDSTENT, 2006 </a> <br> NCT00151658 </td> <td> Cypher<br>  <i>versus</i> <br> Sonic </td> <td> Stable or unstable AP, recent AMI (non ST-elevation); with one or more de novo complex lesions in native coronary vessels (occluded, bifurcational, ostial or angulated) </td> <td> follow-up 7 months<br> n=163/159<br> Parallel groups<br> open <br> Denmark </td> </tr> <tr> <td> <a href="index.html"> TYPHOON, 2006 </a> <br> NCT00232830 </td> <td> Cypher or CypherSelect<br>  <i>versus</i> <br> any commerciallyavailable uncoated stent </td> <td> AMI </td> <td> follow-up 12 months<br> n=356/359<br> Parallel groups<br> open <br> Worldwide (15 countries) </td> </tr> <tr> <td> <a href="index.html"> SESAMI, 2007 </a> <br> NCT00288210 </td> <td> Cypher<br>  <i>versus</i> <br> BX stent, Cordis </td> <td> AMI </td> <td> follow-up 12 months<br> n=160/160<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> DECODE, 2005 </a> <br> NCT00489164 </td> <td> CYPHER (Up to 3 stents per patient were allowed)<br>  <i>versus</i> <br> Bx VELOCITY (Up to 3 stents per patient were allowed) </td> <td> Stable or unstable angina in diabetic patients with with up to 2 de novo lesions in up to 2 native coronary vessels </td> <td> follow-up 1 year<br> n=54/29<br> Parallel groups<br> open <br> US, Asia/Pacific </td> </tr> <tr> <td> <a href="index.html"> SCORPIUS, 2007 </a> <br> NCT00495898 </td> <td> Cypher<br>  <i>versus</i> <br> Bx-Velocity </td> <td> patients with diabetes and de novo coronary artery lesions </td> <td> follow-up 12 months<br> n=98/102<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> MISSION, 2008 </a> <br> ISRCTN62825862 </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (<9h) </td> <td> follow-up 12 months<br> n=158/152<br> Parallel groups<br> single-blind <br> the Netherlands </td> </tr> <tr> <td> <a href="index.html"> Ortolani et al, 2007 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> symptomatic coronary artery disease and target vessel diameter appropriate for implantation a 3-mm stent </td> <td> follow-up 9 months<br> n=-9/-9<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> TAXi, 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients </td> <td> follow-up 6 months<br> n=102/100<br> Parallel groups<br> open <br> Switzerland. </td> </tr> <tr> <td> <a href="index.html"> ISAR-DESIRE (SES vs PES), 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> In-stent restenosis. AP and/or positive test, previously stented, no AMI </td> <td> follow-up 1y<br> n=100/100<br> Parallel groups<br> open <br> germany </td> </tr> <tr> <td> <a href="index.html"> ISAR-DIABETES, 2005 </a> <br> </td> <td> Taxus<br>  <i>versus</i> <br> Cypher </td> <td> Diabetic patients. AP or positive stress, no AMI with clinically significant angiographic stenosis in a native coronary vessel </td> <td> follow-up 9 months<br> n=125/125<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> SIRTAX (Windecker), 2005 </a> <br> </td> <td> sirolimus-eluting stents (Cypher)<br>  <i>versus</i> <br> paclitaxel-eluting stents (Taxus) </td> <td> Unselected patients. Stable AP, ACS, including AMI. at least one lesion with stenosis of at least 50 percent in a vessel with a reference diameter between 2.25 and 4.00 mm that was suitable for stent implantation </td> <td> follow-up 9 mo (5y)<br> n=503/509<br> Parallel groups<br> single-blind <br> Switzerland </td> </tr> <tr> <td> <a href="index.html"> CORPAL, 2005 </a> <br> </td> <td> sirolimus<br>  <i>versus</i> <br> paclitaxel </td> <td> Documented myocardial ischaemia, no AMI </td> <td> follow-up <br> n=331/321<br> Parallel groups<br> open <br> Spain </td> </tr> <tr> <td> <a href="index.html"> REALITY, 2006 </a> <br> NCT00235092 </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Relatively unselected patients. Stable or unstable documented silent ischaemia, no AMI with 1 or 2 de novo lesions (2.25-3.00 mm in diameter) in native coronary arteries </td> <td> follow-up 12 months<br> n=701/685<br> Parallel groups<br> open <br> Europe, Latin America, and Asiam </td> </tr> <tr> <td> <a href="index.html"> ISAR-SMART 3, 2006 </a> <br> NCT00146575 </td> <td> Taxus<br>  <i>versus</i> <br> Cypher </td> <td> Small vessels, de novo lesions in native coronary vessels with a diameter of <2.80 mm nondiabetic patients. AP or positive stress, no AMI </td> <td> follow-up <br> n=180/180<br> Parallel groups<br> NA <br> Germany </td> </tr> <tr> <td> <a href="index.html"> Zhang (SES vs PES), 2006 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients. Stable or unstable AP, ACS with de novo coronary lesions </td> <td> follow-up 1y<br> n=246/203<br> Parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> LONG DES II, 2006 </a> <br> </td> <td> SES<br>  <i>versus</i> <br> PES </td> <td> Long lesions. AP or positive stress, no AMI </td> <td> follow-up 9 months<br> n=250/250<br> Parallel groups<br> single-blind <br> Korea </td> </tr> <tr> <td> <a href="index.html"> PROSIT, 2006 </a> <br> </td> <td> SES Cordis<br>  <i>versus</i> <br> PES Boston Scientific </td> <td> AMI or persistent ischaemia 12-24h </td> <td> follow-up 1 year<br> n=154/154<br> Parallel groups<br> open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> SORT OUT II, 2008 </a> <br> NCT00388934 </td> <td> Cypher stent<br>  <i>versus</i> <br> Taxus stent(Boston Scientific Corp) </td> <td> Unselected patients (included ST-segment elevation myocardial infarction (STEMI), non-STEMI or unstable angina pectoris, and stable angina) </td> <td> follow-up <br> n=1065/1033<br> Parallel groups<br> open <br> Denmark. </td> </tr> <tr> <td> <a href="index.html"> Cervinka, 2006 </a> <br> </td> <td> sirolimus-eluting stent<br>  <i>versus</i> <br> paclitaxel-eluting stent </td> <td> Complex lesionsand patients. Signs and/or symptoms myocardial ischaemia, including AMI </td> <td> follow-up 6 months<br> n=37/33<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Petronio et al, 2007 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Complex lesions. Stable AP or documented ischaemia, no AMI </td> <td> follow-up 9 months<br> n=50/50<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> Han, 2006 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Multivessel disease. Stable or unstable AP, no AMI </td> <td> follow-up 19.5 months (mean)<br> n=210/206<br> Parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> BASKET (vs paclitaxel), 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> Unselected patients; de-novo lesions </td> <td> follow-up 6 months<br> n=264/281<br> Parallel groups<br> open <br> Switzerland, </td> </tr> <tr> <td> <a href="index.html"> Di Lorenzo et al., 2005 </a> <br> </td> <td> sirolimus<br>  <i>versus</i> <br> paclitaxel </td> <td> ST-segment elevation myocardial infarction </td> <td> follow-up <br> n=90/90<br> Parallel groups<br> open <br> NA </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR II, 2006 </a> <br> </td> <td> AVE Zotarolimus-Eluting Driver<br>  <i>versus</i> <br> Driver </td> <td> single de novo native coronary artery stenosis </td> <td> follow-up 12 months<br> n=598/599<br> Parallel groups<br> double-blind <br> worldwide </td> </tr> <tr> <td> <a href="index.html"> Pasceri, 2003 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up 12 months<br> n=-9/-9<br> Parallel groups<br> <br> </td> </tr> <tr> <td> <a href="index.html"> SPIRIT I, 2005 </a> <br> NCT00180453 </td> <td> everolimus eluting sent, XIENCE<br>  <i>versus</i> <br> bare etal stent, MULTI-LINK VISION </td> <td> patients with de novo native coronary artery lesions </td> <td> follow-up 6 months (5yr)<br> n=28/32<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> LEADERS, 2008 </a> <br> NCT00389220 </td> <td> BioMatrix III (biolimus-eluting stent withbiodegradable polymer)<br>  <i>versus</i> <br> Cypher SELECT (sirolimus-eluting stent with durable polymer) </td> <td> patients aged 18 years or older with chronic stable coronary artery disease or acute coronary syndromes </td> <td> follow-up 9 months<br> n=857/850<br> Parallel groups<br> open assessor-blind <br> Europe </td> </tr> <tr> <td> <a href="index.html"> GISSOC II, 2010 </a> <br> NCT00220558 </td> <td> Sirolimus Eluting Stent<br>  <i>versus</i> <br> Bare Metal Stent </td> <td> patients with Chronic Total Occlusion older than 1 month, and successful recanalization </td> <td> follow-up 8 months<br> n=78/74<br> Parallel groups<br> open <br> Italy </td> </tr> <tr> <td> <a href="index.html"> SPIRIT II, 2006 </a> <br> NCT00180310 </td> <td> everolimus eluting stent, XIENCE V<br>  <i>versus</i> <br> placitaxel eluting stent, TAXUS EXPRESS2 </td> <td> De novo lesions (maximim two) </td> <td> follow-up 6 months<br> n=223/77<br> Parallel groups<br> single-blind (patient) <br> </td> </tr> <tr> <td> <a href="index.html"> SYNTAX, 2009 </a> <br> NCT00114972 </td> <td> paclitaxel (taxus Express SR)<br>  <i>versus</i> <br> Coronary Artery Bypass Surgery (on- or off-pump bypass) </td> <td> patients with previously untreated three-vessel or left main coronary artery disease (or both) (complex lesions) </td> <td> follow-up 1 year<br> n=903/897<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR III, 2006 </a> <br> NCT00217256 </td> <td> ABT-578 coated Endeavor<br>  <i>versus</i> <br> Cypher </td> <td> single de novo lesions in native coronary arteries 2.5-3.5 mm in diameter </td> <td> follow-up 12 months (and 24 months)<br> n=327/109<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> ENDEAVOR IV, 2009 </a> <br> NCT00217269 </td> <td> zotarolimus-eluting stent (Endeavor)<br>  <i>versus</i> <br> paclitaxel-eluting stent (Taxus) </td> <td> single de novo lesions in native coronary arteries with a reference vessel diameter of 2.5-3.5 mm </td> <td> follow-up mean 36 mo<br> n=773/775<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> SPIRIT IV, 2010 </a> <br> NCT00307047 </td> <td> XIENCE V Everolimus Eluting Coronary Stent System<br>  <i>versus</i> <br> TAXUS EXPRESS2 Paclitaxel Eluting Coronary Stent System (TAXUS). </td> <td> patients with de novo native coronary artery lesions and reference vessel diameters between 2.5 mm to 4.25 mm and lesion lengths <= 28 mm </td> <td> follow-up 1 y (2y)<br> n=2458/1229<br> Parallel groups<br> 270 days (5 years) <br> USA </td> </tr> <tr> <td> <a href="index.html"> SPIRIT III, 2008 </a> <br> NCT00180479 </td> <td> everolimus-eluting stent, XIENCE V<br>  <i>versus</i> <br> paclitaxel-eluting stent, Taxus </td> <td> lesions 28 mm or less in length and with reference vessel diameter between 2.5 and 3.75 m </td> <td> follow-up 12 months<br> n=669/333<br> Parallel groups<br> single-blind <br> US </td> </tr> <tr> <td> <a href="index.html"> ISAR-TEST-1, 2006 </a> <br> NCT00140530 </td> <td> rapamycin-eluting stent Yukon<br>  <i>versus</i> <br> Taxus </td> <td> stable or unstable anginaor a positive stress test, stable or unstable anginaor a positive stress test </td> <td> follow-up 9 months<br> n=225/225<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ISAR-LEFT-MAIN, 2009 </a> <br> NCT00133237 </td> <td> Paclitaxel-eluting stent<br>  <i>versus</i> <br> Sirolimus-eluting stent </td> <td> Unprotected Left Main Coronary Artery Disease </td> <td> follow-up 1 year<br> n=302/305<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> SORT OUT IV, 0 </a> <br> NCT00552877 </td> <td> everolimus-eluting stents<br>  <i>versus</i> <br> sirolimus-eluting stents </td> <td> unselected patients with coronary artery disease </td> <td> follow-up 9 months (3 years)<br> n=1390/1384<br> Parallel groups<br> open <br> Denmark </td> </tr> <tr> <td> <a href="index.html"> ZEST (vs SES), 2009 </a> <br> NCT00418067 </td> <td> zotarolimus-eluting stents<br>  <i>versus</i> <br> sirolimus-eluting stents </td> <td> Patients with coronary artery disease </td> <td> follow-up 1 year<br> n=883/878<br> Parallel groups<br> Open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> ZEST AMI (vs PES), 2009 </a> <br> NCT00422565 </td> <td> zotarolimus-eluting stent (Endeavor) <br>  <i>versus</i> <br> paclitaxel-eluting stent (Taxus Liberté) </td> <td> Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours </td> <td> follow-up 1 year (mean)<br> n=108/110<br> <br> open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> Dakik, 1998 </a> <br> </td> <td> PTCA<br>  <i>versus</i> <br> intensive medical therapy </td> <td> stable survivors of AMI </td> <td> follow-up 1y<br> n=19/22<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ALKK, 2003 </a> <br> </td> <td> angioplasty<br>  <i>versus</i> <br> medical therapy </td> <td> patients with single vessel disease of the infarct vessel and no or minor angina pectoris in the subacute phase (1 to 6 weeks) after an acute myocardial infarction </td> <td> follow-up 4.7y<br> n=149/151<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> Hambrecht, 2004 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> 12 months of exercise training (20 minutes of bicycle ergometry per day) </td> <td> male patients aged 70 years </td> <td> follow-up 1y<br> n=50/51<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Bech, 2001 </a> <br> </td> <td> PTCA<br>  <i>versus</i> <br> deferral of PTCA </td> <td> patients with planned PTCA and no documented ischemia and with coronary pressurederived fractional flow reserve >0.75 </td> <td> follow-up 2y<br> n=90/91<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ARTS, 2001 </a> <br> </td> <td> Palmaz-Schatz Crown/Cross flex (Cordis)<br>  <i>versus</i> <br> Conventional CABG </td> <td> Multi vessel disease with 2 or more de novo lesion in different major arteries Total occlusion < 1month </td> <td> follow-up 1 year<br> n=600/605<br> parallel group<br> open <br> International </td> </tr> <tr> <td> <a href="index.html"> Cisowski, 0 </a> <br> </td> <td> Tristar, Tera, Penta (Guidant) (Cordis)<br>  <i>versus</i> <br> endoscopic atraumatic coronary artery bypass grafting </td> <td> single vessel disease ACC/AHA A or B lesion in proximal LAD Angina CCS II or higher Lesion diameter 3 mm orgreater/length 20mm or greater </td> <td> follow-up 2 years<br> n=50/50<br> parallel group<br> open <br> Poland </td> </tr> <tr> <td> <a href="index.html"> Diegeler, 2002 </a> <br> </td> <td> Various stents<br>  <i>versus</i> <br> minimally invasive direct coronary artery bypass (off-pump proceedure) </td> <td> single vessel disease Lesion =75% stenosis in proximal LAD or between origin of left circumflex and 1st septal branch </td> <td> follow-up 5 years<br> n=110/110<br> parallel group<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> Drenth, 2002 </a> <br> </td> <td> Stent type not reported<br>  <i>versus</i> <br> minimally invasive direct coronary artery bypass (off-pump proceedure </td> <td> single vessel disease Angina II Lesion (Grade B2 or C) of proximal LAD Suitable for CABG or stenting </td> <td> follow-up 6 months, 3 years<br> n=51/51<br> parallel group<br> open <br> Netherlands </td> </tr> <tr> <td> <a href="index.html"> ERACI II, 2003 </a> <br> </td> <td> Gianturco Robin II (Cook) Primary device<br>  <i>versus</i> <br> Conventional CABG </td> <td> multi vessel disease Angina CSS III-IV; no angina but large area of heart at risk; unstable =1 vessel to be treated Lesion>3.0mm </td> <td> follow-up 30d, 1year<br> n=225/225<br> parallel group<br> open <br> Argentinad </td> </tr> <tr> <td> <a href="index.html"> Grip, 2001 </a> <br> </td> <td> Stent type not reported<br>  <i>versus</i> <br> minimally invasive direct coronary artery bypass (off-pump proceedure) </td> <td> single vessel disease engaging LAD Stable or unstable angina </td> <td> follow-up <br> n=28/25<br> parallel group<br> open <br> Sweden </td> </tr> <tr> <td> <a href="index.html"> OCTOSTENT, 2003 </a> <br> NCT00975858 </td> <td> Stent type not reported<br>  <i>versus</i> <br> off-pump coronary artery bypass </td> <td> multi or single vessel disease Moderate LV function CABG or stenting to be considered feasible </td> <td> follow-up 1 year<br> n=138/142<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> SIMA, 2000 </a> <br> </td> <td> Any CE marked, but Palmaz-Schatz recommended<br>  <i>versus</i> <br> Conventional CABG or minimally invasive direct coronary artery bypass (off-pump proceedure) (10% of surgical procedures </td> <td> single vessel disease Symptomatic or silent ischaemia 1 LAD lesion Ejection fraction >45% Vessel >3.0mm </td> <td> follow-up 2.4 years<br> n=62/59<br> parallel group<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> SOS, 2002 </a> <br> NCT00475449 </td> <td> Stent<br>  <i>versus</i> <br> CABG </td> <td> multiple vessel disease Symptomatic 1 or more vessel suitable for stenting </td> <td> follow-up 3 years<br> n=488/500<br> parallel group<br> open <br> Canada, United Kingdom, Europe </td> </tr> <tr> <td> <a href="index.html"> CARDia (PCI), 2008 </a> <br> ISRCTN19872154 </td> <td> PCI plus stenting (and routine abciximab)<br>  <i>versus</i> <br> CABG </td> <td> Patients with diabetes and symptomatic multivessel coronary artery disease or complex single-vessel disease. </td> <td> follow-up 1 y<br> n=256/254<br> Parallel groups<br> open <br> UK, Ireland </td> </tr> <tr> <td> <a href="index.html"> AMIST (Reeves), 2004 </a> <br> </td> <td> percutaneous transluminal coronary angioplasty (PTCA) with or without stenting<br>  <i>versus</i> <br> minimally invasive direct coronary artery bypass grafting (MIDCAB) </td> <td> single-vessel disease (at least 50% stenosis) of the left anterior descending coronary artery (LAD). </td> <td> follow-up 12 months<br> n=50/50<br> Parallel groups<br> open <br> England </td> </tr> <tr> <td> <a href="index.html"> Hong, 2005 </a> <br> </td> <td> drug-eluting stents<br>  <i>versus</i> <br> invasive direct coronary artery bypass (MIDCAB) surgery </td> <td> proximal left anterior descending (LAD) coronary artery stenosis </td> <td> follow-up 9 months<br> n=119/70<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Kim, 2005 </a> <br> </td> <td> Stent<br>  <i>versus</i> <br> MIDCAB using ministernotomy </td> <td> patients with isolated proximal left anterior descending artery disease </td> <td> follow-up 2 years<br> n=50/50<br> Parallel groups<br> open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> Costar II, 2008 </a> <br> NCT00165035 </td> <td> CoStar stent (Conor MedSystems) PES<br>  <i>versus</i> <br> Taxus (Boston Scientific) PES </td> <td> patient undergoing percutaneous coronary intervention for a single lesion per vessel in up to three native epicardial vessels </td> <td> follow-up 8 months (1 year)<br> n=989/686<br> Parallel groups<br> single-blind <br> US, Germany, Belgium, and New Zealand </td> </tr> <tr> <td> <a href="index.html"> TRIAS-HR, 2008 </a> <br> ISRCTN74297220 </td> <td> Genous stent (antibody-coated bare-metal stent) followed by one month of dual antiplatelet therapy<br>  <i>versus</i> <br> Taxus or Cypher followed by at least six months of dual antiplatelet therapy </td> <td> high-risk patients (long lesions, small vessels, chronic total occlusions, or any lesion in a diabetic patient) </td> <td> follow-up 12 months<br> n=98/95<br> Parallel groups<br> single-blind <br> </td> </tr> <tr> <td> <a href="index.html"> Schofield, 1999 </a> <br> </td> <td> Transmyocardial laser revascularisation<br>  <i>versus</i> <br> medical management alone </td> <td> patients with refractory angina </td> <td> follow-up 1 y<br> n=94/94<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Allen, 1999 </a> <br> </td> <td> transmyocardial revascularization<br>  <i>versus</i> <br> medical therapy alone </td> <td> patients with medically refractory class IV angina and coronary disease that could not be treated with percutaneous or surgical revascularization </td> <td> follow-up 1 y<br> n=132/143<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> Frazier, 1999 </a> <br> </td> <td> transmyocardial revascularization<br>  <i>versus</i> <br> continued medical treatment </td> <td> patients with end-stage coronary artery disease </td> <td> follow-up 12 months (4y)<br> n=91/101<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> ATLANTIC (Burkhoff), 1999 </a> <br> </td> <td> Transmyocardial revascularisation<br>  <i>versus</i> <br> medical treatment alone </td> <td> patients with Canadian Cardiovascular Society Angina (CCSA) score III or IV, reversible ischaemia, and incomplete response to other therapies </td> <td> follow-up 1 y<br> n=92/90<br> Parallel groups<br> open <br> US </td> </tr> <tr> <td> <a href="index.html"> Aaberge, 2000 </a> <br> </td> <td> transmyocardial revascularization with CO2-laser<br>  <i>versus</i> <br> continued optimal medical treatment </td> <td> patients with refractory angina not eligible for conventional revascularization </td> <td> follow-up 12 months<br> n=50/50<br> Parallel groups<br> open <br> Norway </td> </tr> <tr> <td> <a href="index.html"> Huikeshoven, 2003 </a> <br> </td> <td> XeCl excimer transmyocardial laser revascularization<br>  <i>versus</i> <br> optimal cardiac medication </td> <td> </td> <td> follow-up 1y<br> n=30/0<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> PACIFIC, 2000 </a> <br> </td> <td> Percutaneous transmyocardial laser revascularisation<br>  <i>versus</i> <br> medical treatment only </td> <td> patients with reversible ischaemia of Canadian Cardiovascular Society angina class III or IV and incomplete response to other therapies </td> <td> follow-up 12 months<br> n=110/111<br> Parallel groups<br> open <br> US, UK </td> </tr> <tr> <td> <a href="index.html"> Galiñanes, 2004 </a> <br> </td> <td> Transmyocardial laser revascularization by holmium: yttrium aluminum garnet laser<br>  <i>versus</i> <br> thoracic sympathectomy </td> <td> patients with nonrevascularizable coronary arteries and intractable angina </td> <td> follow-up 42 months<br> n=10/10<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Stone, 2002 </a> <br> </td> <td> percutaneous transmyocardial revascularization<br>  <i>versus</i> <br> maximal medical therapy </td> <td> patients with class III or IV angina caused by one or more chronically occluded native coronary arteries in which a percutaneous coronary intervention had failed </td> <td> follow-up 6 months<br> n=71/70<br> Parallel groups<br> single blind (patient) <br> US </td> </tr> <tr> <td> <a href="index.html"> Allen, 2000 </a> <br> </td> <td> coronary bypass of suitable vessels plus transmyocardial revascularization to areas not graftable<br>  <i>versus</i> <br> coronary bypass alone with nongraftable areas left unrevascularized </td> <td> patients whose standard of care was coronary artery bypass grafting and who had one or more ischemic areas not amenable to bypass grafting </td> <td> follow-up <br> n=132/131<br> <br> single blind <br> </td> </tr> <tr> <td> <a href="index.html"> Salem, 2004 </a> <br> </td> <td> percutaneous myocardial laser revascularization<br>  <i>versus</i> <br> optimal medical therapy </td> <td> patients with stable angina pectoris (class III or IV) not amenable to conventional revascularization and with evidence of reversible ischemia, ejection fraction >/=25%, and myocardial wall thickness >/=8 mm </td> <td> follow-up 12 months<br> n=40/42<br> Parallel groups<br> double blind <br> Norway </td> </tr> <tr> <td> <a href="index.html"> Loubani, 2003 </a> <br> </td> <td> coronary artery bypass grafting plus transmyocardial laser revascularization with a holmium:YAG (yttrium-aluminum-garnet) laser to nongraftable areas<br>  <i>versus</i> <br> coronary artery bypass grafting </td> <td> Patients who had elective coronary artery bypass with one or more nongraftable coronary arteries </td> <td> follow-up 36 months<br> n=10/10<br> Parallel groups<br> open <br> UK </td> </tr> <tr> <td> <a href="index.html"> van der Sloot, 2004 </a> <br> </td> <td> XeCl excimer transmyocardial laser revascularization<br>  <i>versus</i> <br> maximal medication </td> <td> patients with refractory angina </td> <td> follow-up 12 months<br> n=15/15<br> Parallel groups<br> open <br> the Netherlands </td> </tr> <tr> <td> <a href="index.html"> March, 1999 </a> <br> </td> <td> Transmyocardial laser revascularization<br>  <i>versus</i> <br> continued medical management </td> <td> patients with symptomatic end-stage coronary artery disease </td> <td> follow-up 12 months<br> n=198/0<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Leon (high dose), 2005 </a> <br> </td> <td> high-dose myocardial laser channels<br>  <i>versus</i> <br> placebo (sham procedure) </td> <td> patients with severe angina </td> <td> follow-up 6 months<br> n=98/102<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> Gray, 2003 </a> <br> </td> <td> percutaneous myocardial laser revascularization<br>  <i>versus</i> <br> medical therapy alone </td> <td> with stable angina pectoris (class III or IV) who were unsuitable for conventional revascularization and had evidence of reversible ischemia by thallium-201 scintigraphy, ejection fraction of > or =25%, and myocardial wall thickness > or =8 mm </td> <td> follow-up 12 months<br> n=36/37<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Zhao, 2006 </a> <br> </td> <td> transmyocardial laser revascularization (holmium: YAG) combined with off-pump coronary artery bypass<br>  <i>versus</i> <br> off-pump coronary artery bypass </td> <td> patients with diffusely diseased target vessels </td> <td> follow-up 3.4y<br> n=40/40<br> Parallel groups<br> open <br> China </td> </tr> <tr> <td> <a href="index.html"> TIME, 2001 </a> <br> </td> <td> coronary angiography and revascularisation<br>  <i>versus</i> <br> optimised medical therapy </td> <td> patients aged 75 years or older with chronic angina of at least Canadian Cardiac Society class II despite at least two antianginal drugs </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ISAR-DESIRE (SES vs PTCA), 2005 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> ballon angioplasty </td> <td> In-stent restenosis. AP and/or positive test, previously stented, no AMI </td> <td> follow-up 1y<br> n=100/100<br> Parallel groups<br> open <br> germany </td> </tr> <tr> <td> <a href="index.html"> ISAR-DESIRE (PES vs PTCA), 2005 </a> <br> </td> <td> TAXUS<br>  <i>versus</i> <br> ballon angioplasty </td> <td> In-stent restenosis. AP and/or positive test, previously stented, no AMI </td> <td> follow-up 1y<br> n=100/100<br> Parallel groups<br> open <br> germany </td> </tr> <tr> <td> <a href="index.html"> Pan, 2007 </a> <br> </td> <td> SES for provisional T-stenting<br>  <i>versus</i> <br> PES for provisional T-stenting </td> <td> patients with bifurcation lesions </td> <td> follow-up 24 months (mean)<br> n=103/102<br> Parallel groups<br> open <br> Spain </td> </tr> <tr> <td> <a href="index.html"> BARI 2D, 2009 </a> <br> NCT00006305 </td> <td> prompt revascularization with intensive medical therapy<br>  <i>versus</i> <br> intensive medical therapy alone </td> <td> patients with type 2 diabetes and heart disease </td> <td> follow-up 5.3 y<br> n=1176/1192<br> Parallel groups<br> open <br> US, Canada, Brazil, Mexico, Czech Republic, Austria </td> </tr> <tr> <td> <a href="index.html"> LEMANS, 2002 </a> <br> NCT00375063 </td> <td> unprotected left main stenting<br>  <i>versus</i> <br> coronary artery bypass grafting </td> <td> patients with unprotected left main coronary artery stenosis </td> <td> follow-up 1y<br> n=52/53<br> Parallel groups<br> open <br> Poland </td> </tr> <tr> <td> <a href="index.html"> ZEST AMI (vs SES), 2009 </a> <br> NCT00422565 </td> <td> zotarolimus-eluting stent (Endeavor) <br>  <i>versus</i> <br> sirolimus-eluting stents (Cypher) </td> <td> Acute Myocardial Infarction Patients (STEMI)requiring primary angioplasty with symptom onset <= 12 hours </td> <td> follow-up 1 year (mean)<br> n=108/110<br> Parallel groups<br> open <br> Korea </td> </tr> <tr> <td> <a href="index.html"> ISAR TEST 2 (vs SES), 2009 </a> <br> NCT00332397 </td> <td> dual DES (polymer-free stent consisting of probucol and rapamycin) <br>  <i>versus</i> <br> SES </td> <td> patients with De novo lesions in native coronary arteries </td> <td> follow-up 12 months<br> n=333/335<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ISAR TEST 2 (vs ZES), 2009 </a> <br> NCT00332397 </td> <td> dual DES (polymer-free stent consisting of probucol and rapamycin)<br>  <i>versus</i> <br> permanent polymer zotarolimus-eluting stent (Endeavor) </td> <td> patients with De novo lesions in native coronary arteries </td> <td> follow-up 12 months<br> n=333/339<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ACIP, 1997 </a> <br> </td> <td> revascularization by angioplasty or bypass surgery<br>  <i>versus</i> <br> angina-guided drug therapy or angina plus ischemia-guided drug therapy </td> <td> clinically stable patients with angiographically documented coronary disease (50% stenosis in 1 major vessel or branch) suitable for revascularization </td> <td> follow-up 24 months<br> n=192/366<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> INSPIRE, 2006 </a> <br> </td> <td> coronary revascularization for suppressing scintigraphic ischemia<br>  <i>versus</i> <br> intensive medical therapy strategy </td> <td> Stable survivors of MI, total perfusion defect size 20%, ischemic defect size 10% (by adenosine SPECT), EF 35%t </td> <td> follow-up 60 months<br> n=104/101<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> SWISSI II, 2007 </a> <br> NCT00387231 </td> <td> Percutaneous coronary intervention aimed at full revascularization<br>  <i>versus</i> <br> intensive anti-ischemic drug therapy </td> <td> patients with a recent MI, silent myocardial ischemia verified by stress imaging, and 1- or 2-vessel coronary artery disease </td> <td> follow-up 10.2y<br> n=96/105<br> Parallel groups<br> open <br> Switzerland </td> </tr> <tr> <td> <a href="index.html"> MASS II, 2007 </a> <br> </td> <td> PCI (73% stent)<br>  <i>versus</i> <br> CABG </td> <td> patients with multivessel coronary artery disease with stable angina and preserved ventricular function </td> <td> follow-up 5y (1y)<br> n=205/203<br> Parallel groups<br> open <br> South America </td> </tr> <tr> <td> <a href="index.html"> VA, 1984 </a> <br> </td> <td> coronary-artery bypass grafting<br>  <i>versus</i> <br> medical treatment </td> <td> patients with stable angina </td> <td> follow-up 7 y<br> n=332/354<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ECSS (European), 1988 </a> <br> </td> <td> early coronary bypass surgery<br>  <i>versus</i> <br> medical therapy </td> <td> men with midl or moderate angina pectoris of at least 3 months duration and an obstruction of 50% or more in at least 2 major coronary arteries in the absence of marked LV dysfunction </td> <td> follow-up 12 y<br> n=394/373<br> Parallel groups<br> open <br> Europe (6 countries) </td> </tr> <tr> <td> <a href="index.html"> CASS, 1983 </a> <br> NCT00000489 </td> <td> surgical<br>  <i>versus</i> <br> nonsurgical </td> <td> patients with stable ischemic heart disease </td> <td> follow-up 5y<br> n=390/390<br> Parallel groups<br> open <br> USA, Canada </td> </tr> <tr> <td> <a href="index.html"> Texas, 1977 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=56/60<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Oregon, 1979 </a> <br> </td> <td> surgical treatment<br>  <i>versus</i> <br> medical treatment </td> <td> patients with stable, disabling angina </td> <td> follow-up <br> n=51/49<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> New zealand 1, 1981 </a> <br> </td> <td> surgical<br>  <i>versus</i> <br> nonsurgical </td> <td> men 60 years of age or younger who had recovered from a recurrent myocardial infarction </td> <td> follow-up 4.5 y<br> n=50/50<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Leon (low dose), 2005 </a> <br> </td> <td> low-dose myocardial laser channels<br>  <i>versus</i> <br> placebo (sham procedure) </td> <td> patients with severe angina </td> <td> follow-up 6 months<br> n=98/102<br> Parallel groups<br> double blind <br> US </td> </tr> <tr> <td> <a href="index.html"> ISAR TEST 3 (BP), 2009 </a> <br> </td> <td> biodegradable-polymer 0.4% rapamycin stent (180 mg rapamycin/cm2)<br>  <i>versus</i> <br> permanent-polymer rapamycin-eluting stent (Cypher) (140 mg rapamycin/cm2) </td> <td> Patients with de novo coronary lesions in native vessels </td> <td> follow-up 12 months<br> n=202/202<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ISAR TEST 3 (PF), 2009 </a> <br> </td> <td> polymer free 2% rapamycin (479 mg rapamycin/cm2) stent<br>  <i>versus</i> <br> permanent-polymer rapamycin-eluting stent (Cypher) (140 mg rapamycin/cm2) </td> <td> Patients with de novo coronary lesions in native vessels </td> <td> follow-up 12 months<br> n=201/202<br> <br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ZEST (vs PES), 2009 </a> <br> NCT00418067 </td> <td> zotarolimus-eluting stents<br>  <i>versus</i> <br> paclitaxel-eluting stents </td> <td> Patients with coronary artery disease </td> <td> follow-up 1 year<br> n=883/884<br> <br> NA <br> </td> </tr> <tr> <td> <a href="index.html"> STICH (ventricular reconstruction), 2009 </a> <br> NCT00023595 </td> <td> CABG with surgical ventricular reconstruction<br>  <i>versus</i> <br> CABG </td> <td> patients with anterior-apical regional left ventricular dysfunction </td> <td> follow-up 48 months<br> n=501/499<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Thiele, 2009 </a> <br> NCT00299429 </td> <td> sirolimus-eluting stent<br>  <i>versus</i> <br> MIDCAB surgery </td> <td> isolated LAD disease </td> <td> follow-up 12 months<br> n=65/65<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> ISAR-TEST-4 (biodegradable polymer), 2009 </a> <br> NCT00598676). </td> <td> biodegradable polymer rapamycin-eluting stent<br>  <i>versus</i> <br> permanent polymer-based rapamycin-eluting or everolimus-eluting </td> <td> patients with stable coronary disease or acute coronary syndromes with de novo native-vessel stent implantation </td> <td> follow-up 12 mo<br> n=1299/1304<br> Parallel groups<br> open <br> Germany </td> </tr> <tr> <td> <a href="index.html"> AWESOME, 2001 </a> <br> </td> <td> percutaneous coronary intervention<br>  <i>versus</i> <br> coronary artery bypass graft </td> <td> high-risk patients with medically refractory ischemia </td> <td> follow-up 5 years<br> n=222/232<br> Parallel groups<br> open <br> US (Veterans Affairs Medical Centers) </td> </tr> <tr> <td> <a href="index.html"> Myoprotect, 2004 </a> <br> </td> <td> percutaneous transluminal coronary angioplasty/stent<br>  <i>versus</i> <br> CABG </td> <td> patients with symptomatic main-stem and main-stem-equivalent lesions with substantially increased risk for bypass surgery </td> <td> follow-up 1 year<br> n=23/21<br> Parallel groups<br> open <br> Europe </td> </tr> <tr> <td> <a href="index.html"> RESOLUTE All comers, 2010 </a> <br> NCT00617084.) </td> <td> zotarolimus-eluting stent<br>  <i>versus</i> <br> everolimus-eluting stent (Xience) </td> <td> adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction with or without ST-segment elevation </td> <td> follow-up 12 months (5y)<br> n=1140/1152<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Boudriot, 2008 </a> <br> </td> <td> DES<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up 12 months<br> n=83/84<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> ISAR-CABG, 0 </a> <br> NCT00611910 </td> <td> DES<br>  <i>versus</i> <br> BMS </td> <td> Bypass Graft Lesions </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> PERSEUS Workhorse, 2010 </a> <br> NCT00484315 </td> <td> platinum-chromium alloy, paclitaxel-eluting stent TAXUS Element<br>  <i>versus</i> <br> paclitaxel-eluting stent TAXUS Express 2 </td> <td> De Novo Coronary Artery Lesions; stent patients with lesions <28 mm in length in coronary vessels between 2.75 mm and 4.0 mm in diameter </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> BASKET-SAVAGE, 0 </a> <br> NCT00595647 </td> <td> Taxus<br>  <i>versus</i> <br> Liberté </td> <td> percutaneous coronary interventions of saphenous vein grafts </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> DES-ISR, 0 </a> <br> NCT00485030 </td> <td> Cypher<br>  <i>versus</i> <br> Taxus </td> <td> patients Diffuse Type In-Stent Restenosis After Drug-Eluting Stents Implantation </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> FRE-RACE, 0 </a> <br> NCT00130546 </td> <td> Cypher select<br>  <i>versus</i> <br> Taxus </td> <td> de novo native coronary lesions with two or more coronary artery stenoses </td> <td> follow-up <br> n=-9/-9<br> Cross over<br> <br> </td> </tr> <tr> <td> <a href="index.html"> DIABEDES IV, 0 </a> <br> NCT00552994 </td> <td> Cypher select plus<br>  <i>versus</i> <br> Xience V </td> <td> diabetic patients </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> FOCUS, 0 </a> <br> NCT00485004 </td> <td> sirolimus-eluting implantation cypher<br>  <i>versus</i> <br> cutting balloon angioplasty </td> <td> focal in-stent restenosis after drug-eluting stent </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Lipsia-Yukon-DM, 0 </a> <br> NCT00368953 </td> <td> Yukon Choice stent system<br>  <i>versus</i> <br> Taxus Liberté stent system </td> <td> Patients With Diabetes Mellitus </td> <td> follow-up 9 months<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Nordic Bifurcation Study, 0 </a> <br> NCT00376571 </td> <td> Strategy of Routine Stenting Both Main Vessel and Side Branch<br>  <i>versus</i> <br> Strategy of Routine Main Vessel Stenting and Optional Treatment of Side Branch </td> <td> bifurcation lesions </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> LEFT-MAIN-2, 0 </a> <br> NCT00598637 </td> <td> Xience<br>  <i>versus</i> <br> Endeavor Resolute </td> <td> unprotected left main coronary artery disease </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> VELETI, 0 </a> <br> NCT00289835 </td> <td> TAXUS<br>  <i>versus</i> <br> standard medical treatment </td> <td> Moderate Vein Graft Lesions </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Leipzig, 0 </a> <br> NCT00176397 </td> <td> PCI With DES<br>  <i>versus</i> <br> CABG </td> <td> left main coronary stenosis </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> ZoMaxx phase 2, 0 </a> <br> NCT00140101 </td> <td> ZoMaxx drug-eluting stent<br>  <i>versus</i> <br> TAXUS Express2 </td> <td> de Novo Coronary Artery Lesions </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> PEPCAD IV, 0 </a> <br> NCT00462631 </td> <td> Paclitaxel-eluting PTCA-balloon dilation (SeQuentTM Please) followed by cobalt-chromium stent (CoroflexTM Blue) deployment<br>  <i>versus</i> <br> Taxus Liberté </td> <td> patients with diabetes mellitus </td> <td> follow-up <br> n=-9/-9<br> <br> open <br> </td> </tr> <tr> <td> <a href="index.html"> Nordic Bifurcation Stent Technique Study, 0 </a> <br> NCT00292305 </td> <td> crush stenting<br>  <i>versus</i> <br> culotte stenting </td> <td> bifurcation lesions </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> PROTECT, 0 </a> <br> NCT00476957 </td> <td> Medtronic Endeavor Zotarolimus Eluting Coronary Stent System<br>  <i>versus</i> <br> Cordis Cypher Sirolimus-eluting Coronary Stent </td> <td> unselected patients </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> MIDCAB Versus DES in Proximal LAD Lesions, 0 </a> <br> NCT00299429 </td> <td> sirolimus-coated stent<br>  <i>versus</i> <br> minimally invasive bypass surgery </td> <td> patients with isolated proximal left anterior descending coronary arteries </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> PRISON III, 2007 </a> <br> NCT00428454 </td> <td> Endeavor<br>  <i>versus</i> <br> Cypher </td> <td> patients with total coronary occlusions for at least 2 weeks with evidence of ischemia related to the occluded coronary artery </td> <td> follow-up 8 months<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> FEMH-93005, 0 </a> <br> NCT00190099 </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> GENESIS Trial CP-01, 0 </a> <br> NCT00322569 </td> <td> Corio Pimecrolimus<br>  <i>versus</i> <br> CoStar </td> <td> patients with de novo lesions of the native coronary arteries </td> <td> follow-up 6 months<br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> FREEDOM, 0 </a> <br> NCT00086450 </td> <td> percutaneous coronary stenting<br>  <i>versus</i> <br> CABG </td> <td> diabetic individuals with multivessel coronary artery disease </td> <td> follow-up 5 years<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> TRIAS-Low-Risk , 0 </a> <br> </td> <td> <br>  <i>versus</i> <br> </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> COMBAT, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Korean Randomized Study, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Munich Study, 0 </a> <br> </td> <td> sirolimus<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> REVASCULARIZE, 0 </a> <br> </td> <td> PCI<br>  <i>versus</i> <br> CABG </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> VA CARDS, 0 </a> <br> NCT00326196 </td> <td> percutaneous coronary stenting with drug eluding stents<br>  <i>versus</i> <br> CABG </td> <td> angiographically significant coronary artery disease in diabetes </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> <tr> <td> <a href="index.html"> BASKET-PROVE, 2008 </a> <br> </td> <td> Cypher<br>  <i>versus</i> <br> Vision </td> <td> </td> <td> follow-up <br> n=-9/-9<br> <br> <br> </td> </tr> <tr> <td> <a href="index.html"> Gao, </a> <br> NCT00887211 </td> <td> ProStent rapamycin-eluting stent system<br>  <i>versus</i> <br> Firebird drug-eluting stents </td> <td> </td> <td> follow-up <br> n=-9/-9<br> Parallel groups<br> single blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>RITA 2, 1997 : </b> Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. RITA-2 trial participants <i>Lancet 1997;350:461-8</i> [PMID 9274581] </p> <p> <b>RITA 2, 1997 : </b> Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DASeven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy <i>J Am Coll Cardiol 2003;42:1161-70</i> [PMID 14522473] </p> <p> <b>ACME, 1992 : </b> Parisi AF, Folland ED, Hartigan PA comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. Veterans Affairs ACME Investigators <i>N Engl J Med 1992;326:10-6</i> [PMID 1345754] </p> <p> <b>ACME, 1992 : </b> Hartigan PM, Giacomini JC, Folland ED, Parisi AFTwo- to three-year follow-up of patients with single-vessel coronary artery disease randomized to PTCA or medical therapy (results of a VA cooperative study). Veterans Affairs Cooperative Studies Program ACME Investigators. Angioplasty Compared to Medicine <i>Am J Cardiol 1998;82:1445-50</i> [PMID 9874045] </p> <p> <b>Sievers, 1993 : </b> Sievers N, Hamm CW, Herzner A, Kuck KHMedical therapy versus PTCA: a prospective, randomized trial in patients with asymptomatic coronary single-vessel disease. Abstract. <i>Circulation. 1993;88(suppl I):I-297</i> [PMID 0] </p> <p> <b>MASS, 1995 : </b> Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, Pileggi FThe Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses <i>J Am Coll Cardiol 1995;26:1600-5</i> [PMID 7594092] 10.1016/0735-1097(95)00384-3 </p> <p> <b>BARI, 1996 : </b> Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. <i>N Engl J Med 1996 Jul 25;335:217-25</i> [PMID 8657237] </p> <p> <b>MASS, 1995 : </b> Hueb WA, Bellotti G, de Oliveira SA, Arie S, de Albuquerque CP, Jatene AD, Pileggi FThe Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. <i>J Am Coll Cardiol 1995 Dec;26:1600-5</i> [PMID 7594092] </p> <p> <b>CABRI, 1995 : </b> First-year results of CABRI (Coronary Angioplasty versus Bypass Revascularisation Investigation). CABRI Trial Participants. <i>Lancet 1995 Nov 4;346:1179-84</i> [PMID 7475656] </p> <p> <b>CABRI, 1995 : </b> Martuscelli E, Clementi F, Gallagher MM, D'Eliseo A, Chiricolo G, Nigri A, Marino B, Romeo FRevascularization strategy in patients with multivessel disease and a major vessel chronically occluded; data from the CABRI trial. <i>Eur J Cardiothorac Surg 2008;33:4-8</i> [PMID 17988889] </p> <p> <b>EAST, 1994 : </b> King SB 3rd, Lembo NJ, Weintraub WS, Kosinski AS, Barnhart HX, Kutner MH, Alazraki NP, Guyton RA, Zhao XQA randomized trial comparing coronary angioplasty with coronary bypass surgery. Emory Angioplasty versus Surgery Trial (EAST) <i>N Engl J Med 1994 Oct 20;331:1044-50</i> [PMID 8090163] </p> <p> <b>GABI, 1994 : </b> Hamm CW, Reimers J, Ischinger T, Rupprecht HJ, Berger J, Bleifeld WA randomized study of coronary angioplasty compared with bypass surgery in patients with symptomatic multivessel coronary disease. German Angioplasty Bypass Surgery Investigation (GABI) <i>N Engl J Med 1994 Oct 20;331:1037-43</i> [PMID 8090162] </p> <p> <b>Lausanne, 1994 : </b> Goy JJ, Eeckhout E, Burnand B, Vogt P, Stauffer JC, Hurni M, Stumpe F, Ruchat P, Sadeghi H, Kappenberger LCoronary angioplasty versus left internal mammary artery grafting for isolated proximal left anterior descending artery stenosis. <i>Lancet 1994 Jun 11;343:1449-53</i> [PMID 7911175] </p> <p> <b>RITA, 1993 : </b> Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial. <i>Lancet 1993 Mar 6;341:573-80</i> [PMID 8094826] </p> <p> <b>ERACI, 1992 : </b> Rodriguez A, Boullon F, Perez-Balino N, Paviotti C, Liprandi MI, Palacios IFArgentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group. <i>J Am Coll Cardiol 1993 Oct;22:1060-7</i> [PMID 8409041] </p> <p> <b>WIN, 0 : </b> <i>JACC 1998; 31:80A</i> [PMID 0] </p> <p> <b>WIN, 0 : </b> Bilodeau <i>Eur Heart J 1998 19:48 (suppl)</i> [PMID 0] </p> <p> <b>EPISTENT à effacer doublons, 1998 : </b> Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. <i>Lancet 1998;352:87-92</i> [PMID 9672272] </p> <p> <b>Serruys Benestent 2, 1998 : </b> Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R, Kiemeneij F, Ruygrok P, Ormiston J, Emanuelsson H, Fajadet J, Haude M, Klugmann S, Morel MARandomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) <i>Lancet 1998;352:673-81</i> [PMID 9728982] </p> <p> <b>TASC-I, 1997 : </b> <i>Circulation 1995;92:I475</i> [PMID 0] </p> <p> <b>TASC-I, 1997 : </b> <i>JACC 1995;156A</i> [PMID 0] </p> <p> <b>Versaci , 1997 : </b> Versaci F, Gaspardone A, Tomai F, Crea F, Chiariello L, Gioffre PAA comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. <i>N Engl J Med 1997;336:817-22</i> [PMID 9062089] </p> <p> <b>Fischman STRESS, 1994 : </b> Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi MA randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. <i>N Engl J Med 1994;331:496-501</i> [PMID 8041414] </p> <p> <b>Serruys Benestent, 1994 : </b> Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne PA comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. <i>N Engl J Med 1994;331:489-95</i> [PMID 8041413] </p> <p> <b>Serruys Benestent, 1994 : </b> Macaya C, Serruys PW, Ruygrok P, Suryapranata H, Mast G, Klugmann S, Urban P, den Heijer P, Koch K, Simon R, Morice MC, Crean P, Bonnier H, Wijns W, Danchin N, Bourdonnec C, Morel MAContinued benefit of coronary stenting versus balloon angioplasty: one-year clinical follow-up of Benestent trial. Benestent Study Group. <i>J Am Coll Cardiol 1996;27:255-61</i> [PMID 8557891] </p> <p> <b>ACME 2 (Folland), 1997 : </b> Folland ED, Hartigan PM, Parisi AFPercutaneous transluminal coronary angioplasty versus medical therapy for stable angina pectoris: outcomes for patients with double-vessel versus single-vessel coronary artery disease in a Veterans Affairs Cooperative randomized trial. Veterans Affairs ACME InvestigatorS <i>J Am Coll Cardiol 1997;29:1505-11</i> [PMID 9180111] </p> <p> <b>ACME 2 (Folland), 1997 : </b> Henderson RA, Pocock SJ, Clayton TC, Knight R, Fox KA, Julian DG, Chamberlain DASeven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy <i>J Am Coll Cardiol 2003;42:1161-70</i> [PMID 14522473] </p> <p> <b>AVERT, 1995 : </b> Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, Eisenberg D, Shurzinske L, McCormick LSAggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators <i>N Engl J Med 1999;341:70-6</i> [PMID 10395630] </p> <p> <b>Moer, 2001 : </b> Moer R, Myreng Y, Molstad P, Albertsson P, Gunnes P, Lindvall B, Wiseth R, Ytre-Arne K, Kjekshus J, Golf SStenting in small coronary arteries (SISCA) trial. A randomized comparison between balloon angioplasty and the heparin-coated beStent. <i>J Am Coll Cardiol 2001 Nov 15;38:1598-603</i> [PMID 11704369] </p> <p> <b>Doucet, 2001 : </b> Doucet S, Schalij MJ, Vrolix MC, Hilton D, Chenu P, de Bruyne B, Udayachalerm W, Seth A, Bilodeau L, Reiber JH, Harel F, Lesperance JStent placement to prevent restenosis after angioplasty in small coronary arteries. <i>Circulation 2001 Oct 23;104:2029-33</i> [PMID 11673341] </p> <p> <b>Koning, 2001 : </b> Koning R, Eltchaninoff H, Commeau P, Khalife K, Gilard M, Lipiecki J, Coste P, Bedossa M, Lefevre T, Brunel P, Morice MC, Maillard L, Guyon P, Puel J, Cribier AStent placement compared with balloon angioplasty for small coronary arteries: in-hospital and 6-month clinical and angiographic results. <i>Circulation 2001 Oct 2;104:1604-8</i> [PMID 11581136] </p> <p> <b>Park, 2000 : </b> Park SW, Lee CW, Hong MK, Kim JJ, Cho GY, Nah DY, Park SJRandomized comparison of coronary stenting with optimal balloon angioplasty for treatment of lesions in small coronary arteries. <i>Eur Heart J 2000 Nov;21:1785-9</i> [PMID 11052843] </p> <p> <b>Lotan, 2000 : </b> Lotan C, Rozenman Y, Hendler A, Turgeman Y, Ayzenberg O, Beyar R, Krakover R, Rosenfeld T, Gotsman MSStents in total occlusion for restenosis prevention. The multicentre randomized STOP study. The Israeli Working Group for Interventional Cardiology. <i>Eur Heart J 2000 Dec;21:1960-6</i> [PMID 11071802] </p> <p> <b>Weaver, 2000 : </b> Weaver WD, Reisman MA, Griffin JJ, Buller CE, Leimgruber PP, Henry T, D'Haem C, Clark VL, Martin JS, Cohen DJ, Neil N, Every NROptimum percutaneous transluminal coronary angioplasty compared with routine stent strategy trial (OPUS-1): a randomised trial. <i>Lancet 2000 Jun 24;355:2199-203</i> [PMID 10881893] </p> <p> <b>Dangas, 2000 : </b> Dangas G, Ambrose JA, Rehmann D, Marmur JD, Sharma SK, Hemdal-Monsen C, Sanborn TA, Fischman DLBalloon optimization versus stent study (BOSS): provisional stenting and early recoil after balloon angioplasty. <i>Am J Cardiol 2000 Apr 15;85:957-61</i> [PMID 10760334] </p> <p> <b>Fluck, 2000 : </b> Fluck DS, Chenu P, Mills P, Davies A, Street J, Paul E, Balcon R, Layton CAIs provisional stenting the effective option? The WIDEST study (Wiktor stent in de novo stenosis). Widest Trial Investigators' Group. <i>Heart 2000 Nov;84:522-8</i> [PMID 11040014] </p> <p> <b>Lafont, 2000 : </b> Lafont A, Dubois-Rande JL, Steg PG, Dupouy P, Carrie D, Coste P, Furber A, Beygui F, Feldman LJ, Rahal S, Tron C, Hamon M, Grollier G, Commeau P, Richard P, Colin P, Bauters C, Karrillon G, Ledru F, Citron B, Marie FN, Kern MThe French Randomized Optimal Stenting Trial: a prospective evaluation of provisional stenting guided by coronary velocity reserve and quantitative coronary angiography. F.R.O.S.T. Study Group. <i>J Am Coll Cardiol 2000 Aug;36:404-9</i> [PMID 10933349] </p> <p> <b>Witkowski, 2000 : </b> Witkowski A, Ruzyllo W, Gil R, Gorecka B, Purzycki Z, Kosmider M, Polonski L, Lekston A, Gasior M, Zmudka K, Pieniazek P, Buszman P, Drzewiecki J, Ciecwierz D, Sadowski ZA randomized comparison of elective high-pressure stenting with balloon angioplasty: six-month angiographic and two-year clinical follow-up. On behalf of AS (Angioplasty or Stent) trial investigators. <i>Am Heart J 2000 Aug;140:264-71</i> [PMID 10925341] </p> <p> <b>Kastrati, 2000 : </b> Kastrati A, Schomig A, Dirschinger J, Mehilli J, Dotzer F, von Welser N, Neumann FJA randomized trial comparing stenting with balloon angioplasty in small vessels in patients with symptomatic coronary artery disease. ISAR-SMART Study Investigators. Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries. <i>Circulation 2000 Nov 21;102:2593-8</i> [PMID 11085962] </p> <p> <b>Di Marlo, 2000 : </b> Di Mario C, Moses JW, Anderson TJ, Bonan R, Muramatsu T, Jain AC, Suarez de Lezo J, Cho SY, Kern M, Meredith IT, Cohen D, Moussa I, Colombo ARandomized comparison of elective stent implantation and coronary balloon angioplasty guided by online quantitative angiography and intracoronary Doppler. DESTINI Study Group (Doppler Endpoint STenting INternational Investigation). <i>Circulation 2000 Dec 12;102:2938-44</i> [PMID 11113043] </p> <p> <b>Serruys, 2000 : </b> Serruys PW, de Bruyne B, Carlier S, Sousa JE, Piek J, Muramatsu T, Vrints C, Probst P, Seabra-Gomes R, Simpson I, Voudris V, Gurne O, Pijls N, Belardi J, van Es GA, Boersma E, Morel MA, van Hout BRandomized comparison of primary stenting and provisional balloon angioplasty guided by flow velocity measurement. Doppler Endpoints Balloon Angioplasty Trial Europe (DEBATE) II Study Group. <i>Circulation 2000 Dec 12;102:2930-7</i> [PMID 11113042] </p> <p> <b>Lincoff (EPISTENT), 1999 : </b> Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cabot CF, Topol EJComplementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. <i>N Engl J Med 1999 Jul 29;341:319-27</i> [PMID 10423466] </p> <p> <b>Lincoff (EPISTENT), 1999 : </b> |Z <i>Lancet 1998 Jul 11;352:87-92</i> [PMID 9672272] </p> <p> <b>Buller, 1999 : </b> Buller CE, Dzavik V, Carere RG, Mancini GB, Barbeau G, Lazzam C, Anderson TJ, Knudtson ML, Marquis JF, Suzuki T, Cohen EA, Fox RS, Teo KKPrimary stenting versus balloon angioplasty in occluded coronary arteries: the Total Occlusion Study of Canada (TOSCA). <i>Circulation 1999 Jul 20;100:236-42</i> [PMID 10411846] </p> <p> <b>Betriu, 1999 : </b> Betriu A, Masotti M, Serra A, Alonso J, Fernandez-Aviles F, Gimeno F, Colman T, Zueco J, Delcan JL, Garcia E, Calabuig JRandomized comparison of coronary stent implantation and balloon angioplasty in the treatment of de novo coronary artery lesions (START): a four-year follow-up. <i>J Am Coll Cardiol 1999 Nov 1;34:1498-506</i> [PMID 10551699] </p> <p> <b>Hoher, 1999 : </b> Hoher M, Wohrle J, Grebe OC, Kochs M, Osterhues HH, Hombach V, Buchwald ABA randomized trial of elective stenting after balloon recanalization of chronic total occlusions. <i>J Am Coll Cardiol 1999 Sep;34:722-9</i> [PMID 10483953] </p> <p> <b>Sievert, 1999 : </b> Sievert H, Rohde S, Utech A, Schulze R, Scherer D, Merle H, Ensslen R, Schrader R, Spies H, Fach AStent or angioplasty after recanalization of chronic coronary occlusions? (The SARECCO Trial). <i>Am J Cardiol 1999 Aug 15;84:386-90</i> [PMID 10468073] </p> <p> <b>Eeckout, 1996 : </b> Eeckhout E, Stauffer JC, Vogt P, Debbas N, Kappenberger L, Goy JJComparison of elective Wiktor stent placement with conventional balloon angioplasty for new-onset lesions of the right coronary artery. <i>Am Heart J 1996 Aug;132:263-8</i> [PMID 8701885] </p> <p> <b>Sirnes, 1996 : </b> Sirnes PA, Golf S, Myreng Y, Molstad P, Emanuelsson H, Albertsson P, Brekke M, Mangschau A, Endresen K, Kjekshus JStenting in Chronic Coronary Occlusion (SICCO): a randomized, controlled trial of adding stent implantation after successful angioplasty. <i>J Am Coll Cardiol 1996 Nov 15;28:1444-51</i> [PMID 8917256] </p> <p> <b>Savage, 1998 : </b> Savage MP, Douglas JS Jr, Fischman DL, Pepine CJ, King SB 3rd, Werner JA, Bailey SR, Overlie PA, Fenton SH, Brinker JA, Leon MB, Goldberg SStent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators. <i>N Engl J Med 1997 Sep 11;337:740-7</i> [PMID 9287229] </p> <p> <b>Erbel, 1998 : </b> Erbel R, Haude M, Hopp HW, Franzen D, Rupprecht HJ, Heublein B, Fischer K, de Jaegere P, Serruys P, Rutsch W, Probst PCoronary-artery stenting compared with balloon angioplasty for restenosis after initial balloon angioplasty. Restenosis Stent Study Group. <i>N Engl J Med 1998 Dec 3;339:1672-8</i> [PMID 9834304] </p> <p> <b>Rubartelli, 1998 : </b> Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini GStent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. <i>J Am Coll Cardiol 1998 Jul;32:90-6</i> [PMID 9669254] </p> <p> <b>Rubartelli, 1998 : </b> Rubartelli P, Niccoli L, Verna E, Giachero C, Zimarino M, Fontanelli A, Vassanelli C, Campolo L, Martuscelli E, Tommasini GStent implantation versus balloon angioplasty in chronic coronary occlusions: results from the GISSOC trial. Gruppo Italiano di Studio sullo Stent nelle Occlusioni Coronariche. <i>J Am Coll Cardiol 1998 Jul;32:90-6</i> [PMID 9669254] </p> <p> <b>Hancock, 1998 : </b> Hancock J, Thomas MR, Holmberg S, Wainwright RJ, Jewitt DERandomised trial of elective stenting after successful percutaneous transluminal coronary angioplasty of occluded coronary arteries. <i>Heart 1998 Jan;79:18-23</i> [PMID 9505913] </p> <p> <b>Rodriguez, 1998 : </b> Rodriguez A, Ayala F, Bernardi V, Santaera O, Marchand E, Pardinas C, Mauvecin C, Vogel D, Harrell LC, Palacios IFOptimal coronary balloon angioplasty with provisional stenting versus primary stent (OCBAS): immediate and long-term follow-up results. <i>J Am Coll Cardiol 1998 Nov;32:1351-7</i> [PMID 9809947] </p> <p> <b>COURAGE, 2007 : </b> Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, Chaitman BR, Shaw L, Gosselin G, Nawaz S, Title LM, Gau G, Blaustein AS, Booth DC, Bates ER, Spertus JA, Berman DS, Mancini GB, Weintraub WSOptimal medical therapy with or without PCI for stable coronary disease. <i>N Engl J Med 2007 Apr 12;356:1503-16</i> [PMID 17387127] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JAFive-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease <i>Circulation 2007;115:1082-9</i> [PMID 17339566] 10.1161/CIRCULATIONAHA.106.625475 </p> <p> <b>MASS II, 2007 : </b> Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JAThe medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. <i>J Am Coll Cardiol 2004;43:1743-51</i> [PMID 15145093] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JATen-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2010;122:949-57</i> [PMID 20733102] 10.1161/CIRCULATIONAHA.109.911669 </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JAFive-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2007 Mar 6;115:1082-9</i> [PMID 17339566] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JATen-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2010;122:949-57</i> [PMID 20733102] 10.1161/CIRCULATIONAHA.109.911669 </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JAFive-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2007 Mar 6;115:1082-9</i> [PMID 17339566] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Soares PR, Gersh BJ, César LA, Luz PL, Puig LB, Martinez EM, Oliveira SA, Ramires JAThe medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. <i>J Am Coll Cardiol 2004;43:1743-51</i> [PMID 15145093] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JATen-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2010;122:949-57</i> [PMID 20733102] 10.1161/CIRCULATIONAHA.109.911669 </p> <p> <b>Tomai, 2008 : </b> Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffr G, Prati F, Tamburino C, Ribichini F, Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study. <i>Diabetes Care 2008;31:15-9.</i> [PMID 17909090] 10.2337/dc07-1377 </p> <p> <b>Kochiadakis, 2007 : </b> Kochiadakis GE, Marketou ME, Arfanakis DA, Sfiridaki K, Skalidis EI, Igoumenidis NE, Hamilos MI, Kolyvaki S, Chlouverakis G, Kantidaki E, Castanas E, Vardas PE, Reduced systemic inflammatory response to implantation of sirolimus-eluting stents in patients with stable coronary artery disease. <i>Atherosclerosis 2007;194:433-8.</i> [PMID 16997310] 10.1016/j.atherosclerosis.2006.08.029 </p> <p> <b>RAVEL, 2002 : </b> Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnr F, Falotico RA randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. <i>N Engl J Med 2002;346:1773-80</i> [PMID 12050336] </p> <p> <b>RAVEL, 2002 : </b> Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa ELong-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. <i>J Am Coll Cardiol 2007 Oct 2;50:1299-304</i> [PMID 17903626] </p> <p> <b>SIRIUS, 2003 : </b> Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RESirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. <i>N Engl J Med 2003;349:1315-23</i> [PMID 14523139] </p> <p> <b>SIRIUS, 2003 : </b> Weisz G, Moses JW, Teirstein PS, Holmes DR Jr, Raizner AE, Satler LF, Mishkel G, Wilensky RL, Wang P, Kuntz RE, Popma JJ, Leon MBSafety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy). <i>Am J Cardiol 2007 Apr 15;99:1044-50</i> [PMID 17437725] </p> <p> <b>SIRIUS, 2003 : </b> Holmes DR Jr, Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz REAnalysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. <i>Circulation 2004;109:634-40</i> [PMID 14769686] </p> <p> <b>SIRIUS, 2003 : </b> Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Popma JJ, Teirstein PS, Cohen SA, Wang H, Cutlip DE, Moses JWFive-year follow-up after sirolimus-eluting stent implantation results of the SIRIUS (Sirolimus-Eluting Stent in De-Novo Native Coronary Lesions) Trial. <i>J Am Coll Cardiol 2009 Apr 28;53:1488-97</i> [PMID 19389558] 10.1016/j.jacc.2009.01.050 </p> <p> <b>SIRIUS, 2003 : </b> Novack V, Nguyen MC, Rooney M, Chacko R, Novack L, Pencina M, Apruzzese P, Mauri L, Cohen SA, Moses J, Leon MB, Cutlip DEEffect of coronary target lesion revascularization on late cardiac events after insertion of sirolimus-eluting or bare metal stents. <i>Am J Cardiol 2010 Sep 15;106:774-9</i> [PMID 20816116] 10.1016/j.amjcard.2010.04.039 </p> <p> <b>C-SIRIUS, 2004 : </b> Schampaert E, Cohen EA, Schlter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJThe Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). <i>J Am Coll Cardiol 2004;43:1110-5</i> [PMID 15028375] </p> <p> <b>E-SIRIUS, 2003 : </b> Schofer J, Schlter M, Gershlick AH, Wijns W, Garcia E, Schampaert E, Breithardt GSirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). <i>Lancet 2003;362:1093-9</i> [PMID 14550694] </p> <p> <b>TAXUS I, 2003 : </b> Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell METAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. <i>Circulation 2003;107:38-42</i> [PMID 12515740] </p> <p> <b>TAXUS I, 2003 : </b> Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell METAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. <i>Circulation 2003 Jan 7;107:38-42</i> [PMID 12515740] </p> <p> <b>TAXUS II, 2003 : </b> Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell MERandomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. <i>Circulation 2003;108:788-94</i> [PMID 12900339] </p> <p> <b>TAXUS II, 2003 : </b> Silber S, Colombo A, Banning AP, Hauptmann K, Drzewiecki J, Grube E, Dudek D, Baim DSFinal 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions. <i>Circulation 2009 Oct 13;120:1498-504</i> [PMID 19786634] </p> <p> <b>TAXUS IV, 2004 : </b> Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell MEA polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. <i>N Engl J Med 2004;350:221-31</i> [PMID 14724301] </p> <p> <b>TAXUS IV, 2004 : </b> Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DSLong-Term Safety and Efficacy With Paclitaxel-Eluting Stents 5-Year Final Results of the TAXUS IV Clinical Trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). <i>JACC Cardiovasc Interv 2009 Dec;2:1248-59</i> [PMID 20129552] 10.1016/j.jcin.2009.10.003 </p> <p> <b>TAXUS IV, 2004 : </b> Ellis SG, Stone GW, Cox DA, Hermiller J, O'Shaughnessy C, Mann T, Turco M, Caputo R, Bergin PJ, Bowman TS, Baim DSLong-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent). <i>JACC Cardiovasc Interv 2009;2:1248-59</i> [PMID 20129552] 10.1016/j.jcin.2009.10.003 </p> <p> <b>ASPECT, 2003 : </b> Park SJ, Shim WH, Ho DS, Raizner AE, Park SW, Hong MK, Lee CW, Choi D, Jang Y, Lam R, Weissman NJ, Mintz GSA paclitaxel-eluting stent for the prevention of coronary restenosis. <i>N Engl J Med 2003;348:1537-45</i> [PMID 12700373] </p> <p> <b>ELUTES, 2004 : </b> Gershlick A, De Scheerder I, Chevalier B, Stephens-Lloyd A, Camenzind E, Vrints C, Reifart N, Missault L, Goy JJ, Brinker JA, Raizner AE, Urban P, Heldman AWInhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. <i>Circulation 2004;109:487-93</i> [PMID 14744971] </p> <p> <b>DELIVER, 2004 : </b> ONeill WW, Knopf W, Lansky A, Fitzgerald P, Mahaffey K.Randomized comparison of paclitaxel-coated versus metallic stentsfor treatment of coronary lesions <i>American College of CardiologyScientific Session, March, 2003</i> [PMID ] </p> <p> <b>DELIVER, 2004 : </b> Knopf W, ONeill WW, Lansky A, Fitzgerald P, Mahaffey KERandomized comparison of paclitaxel-coated versus metallicstents for treatment of coronary lesions <i>TranscatheterCardiovascular Therapeutics Annual Meeting, September, 2003</i> [PMID ] </p> <p> <b>DELIVER, 2004 : </b> Lansky AJ, Costa RA, Mintz GS, Tsuchiya Y, Midei M, Cox DA, O'Shaughnessy C, Applegate RA, Cannon LA, Mooney M, Farah A, Tannenbaum MA, Yakubov S, Kereiakes DJ, Wong SC, Kaplan B, Cristea E, Stone GW, Leon MB, Knopf WD, O'Neill WWNon-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. <i>Circulation 2004 Apr 27;109:1948-54</i> [PMID 15078794] </p> <p> <b>PATENCY, 2002 : </b> Heldman A, Farhat N, Fry E, et al.bPaclitaxel-eluting stent for cytostatic prevention of restenosis: the PATENCY Study <i>Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002</i> [PMID ] </p> <p> <b>SCORE, 2004 : </b> Stone GW.Adverse outcomes from a taxane-loaded polymericsleeved stent: final results from the SCORE Tria <i>AmericanCollege of Cardiology Scientific Session, March, 2002</i> [PMID ] </p> <p> <b>SCORE, 2004 : </b> Grube E, Lansky A, Hauptmann KE, Di Mario C, Di Sciascio G, Colombo A, Silber S, Stumpf J, Reifart N, Fajadet J, Marzocchi A, Schofer J, Dumas P, Hoffmann R, Guagliumi G, Pitney M, Russell MEHigh-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: one-year results from the SCORE randomized trial. <i>J Am Coll Cardiol 2004 Oct 6;44:1368-72</i> [PMID 15464315] </p> <p> <b>ACTION, 2004 : </b> Serruys PW, Veldhof S, Stuteville M, et alActinomycin-elutingstent improves outcome by reducing neointimal hyperplasia <i>Transcatheter Cardiovascular Therapeutics Annual Meeting,September, 2002</i> [PMID ] </p> <p> <b>ACTION, 2004 : </b> Serruys PW, Ormiston JA, Sianos G, Sousa JE, Grube E, den Heijer P, de Feyter P, Buszman P, Schmig A, Marco J, Polonski L, Thuesen L, Zeiher AM, Bett JH, Suttorp MJ, Glogar HD, Pitney M, Wilkins GT, Whitbourn R, Veldhof S, Miquel K, Johnson R, Coleman L,Actinomycin-eluting stent for coronary revascularization: a randomized feasibility and safety study: the ACTION trial. <i>J Am Coll Cardiol 2004 Oct 6;44:1363-7</i> [PMID 15464314] </p> <p> <b>FUTURE I, 2004 : </b> Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJSix- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. <i>Circulation 2004;109:2168-71</i> [PMID 15123533] </p> <p> <b>FUTURE II, 2006 : </b> Grube E, Lansky A, Mehran R, Fitzgerald P, HoMulticenter evaluation of the bioabsorbable polymer-basedeverolimus-eluting stent: FUTURE-2 trial <i>TranscatheterCardiovascular Therapeutic Annual Meeting, September, 2003</i> [PMID ] </p> <p> <b>FUTURE II, 2006 : </b> Tsuchiya Y, Lansky AJ, Costa RA, Mehran R, Pietras C, Shimada Y, Sonoda S, Cristea E, Negoita M, Dangas GD, Moses JW, Leon MB, Fitzgerald PJ, Mller R, Strger H, Hauptmann KE, Grube EEffect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). <i>Am J Cardiol 2006 Aug 15;98:464-9</i> [PMID 16893698] </p> <p> <b>FUTURE II, 2006 : </b> Grube E, Sonoda S, Ikeno F, Honda Y, Kar S, Chan C, Gerckens U, Lansky AJ, Fitzgerald PJSix- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. <i>Circulation 2004 May 11;109:2168-71</i> [PMID 15123533] </p> <p> <b>TAXUS V (all patients), 2005 : </b> Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, O'Shaughnessy CD, DeMaio S, Hall P, Popma JJ, Koglin J, Russell MEComparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. <i>JAMA 2005;294:1215-23</i> [PMID 16160130] </p> <p> <b>TAXUS VI, 2005 : </b> Dawkins KD, Grube E, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Koglin J, Russell MEClinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. <i>Circulation 2005;112:3306-13</i> [PMID 16286586] </p> <p> <b>TAXUS VI, 2005 : </b> Grube E, Dawkins KD, Guagliumi G, Banning AP, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma JJ, Buellesfeld L, Koglin J, Russell METAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions. <i>Eur Heart J 2007;28:2578-82</i> [PMID 17938126] </p> <p> <b>TAXUS VI, 2005 : </b> Grube E, Dawkins K, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Joshi A, Mascioli STAXUS VI final 5-year results: a multicentre, randomised trial comparing polymer-based moderate-release paclitaxel-eluting stent with a bare metal stent for treatment of long, complex coronary artery lesions. <i>EuroIntervention 2009;4:572-7</i> [PMID 19378676] </p> <p> <b>PASSION, 2006 : </b> Laarman GJ, Suttorp MJ, Dirksen MT, van Heerebeek L, Kiemeneij F, Slagboom T, van der Wieken LR, Tijssen JG, Rensing BJ, Patterson MPaclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. <i>N Engl J Med 2006;355:1105-13</i> [PMID 16971717] </p> <p> <b>PASSION, 2006 : </b> Dirksen MT, Vink MA, Suttorp MJ, Tijssen JG, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ <i>EuroIntervention 2008 May;4:64-70</i> [PMID 19112781] </p> <p> <b>HAAMU-STENT, 2006 : </b> Tierala I, Syvaenne M, Kupari MRandomised comparison of apaclitaxel-eluting and a bare metal stent in STEMI-PCI. TheHAAMU-STENT-study <i>Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics; Washington, DC;Oct 2227, 2006. Abstract 178.</i> [PMID ] </p> <p> <b>SES-SMART, 2004 : </b> Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PASirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. <i>JAMA 2004;292:2727-34</i> [PMID 15585732] </p> <p> <b>DIABETES, 2005 : </b> Sabat M, Jimnez-Quevedo P, Angiolillo DJ, Gmez-Hospital JA, Alfonso F, Hernndez-Antoln R, Goicolea J, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya CRandomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. <i>Circulation 2005;112:2175-83</i> [PMID 16203930] </p> <p> <b>DIABETES, 2005 : </b> Jimnez-Quevedo P, Sabat M, Angiolillo DJ, Alfonso F, Hernndez-Antoln R, SanMartn M, Gmez-Hospital JA, Bauelos C, Escaned J, Moreno R, Fernndez C, Fernndez-Avils F, Macaya CLong-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. <i>Eur Heart J 2007;28:1946-52</i> [PMID 17562666] </p> <p> <b>DIABETES, 2005 : </b> Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L <i>Am J Cardiol 2009 Feb 1;103:345-9</i> [PMID 19166687] </p> <p> <b>Pache et al, 2005 : </b> Pache J, Dibra A, Mehilli J, Dirschinger J, Schmig A, Kastrati ADrug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. <i>Eur Heart J 2005;26:1262-8</i> [PMID 15737962] </p> <p> <b>PRISON II, 2006 : </b> Suttorp MJ, Laarman GJ, Rahel BM, Kelder JC, Bosschaert MA, Kiemeneij F, Ten Berg JM, Bal ET, Rensing BJ, Eefting FD, Mast EGPrimary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): a randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions. <i>Circulation 2006;114:921-8</i> [PMID 16908768] </p> <p> <b>SCANDSTENT, 2006 : </b> Kelbaek H, Thuesen L, Helqvist S, Klvgaard L, Jrgensen E, Aljabbari S, Saunamki K, Krusell LR, Jensen GV, Btker HE, Lassen JF, Andersen HR, Thayssen P, Galle A, van Weert AThe Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. <i>J Am Coll Cardiol 2006;47:449-55</i> [PMID 16412876] </p> <p> <b>SCANDSTENT, 2006 : </b> Kelbaek H, Klvgaard L, Helqvist S, Lassen JF, Krusell LR, Engstrm T, Btker HE, Jrgensen E, Saunamki K, Aljabbari S, Thayssen P, Galle A, Jensen GV, Thuesen LLong-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial. <i>J Am Coll Cardiol 2008 May 27;51:2011-6</i> [PMID 18498953] </p> <p> <b>TYPHOON, 2006 : </b> Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode CSirolimus-eluting versus uncoated stents in acute myocardial infarction. <i>N Engl J Med 2006;355:1093-104</i> [PMID 16971716] </p> <p> <b>SESAMI, 2007 : </b> Menichelli M, Parma A, Pucci E, Fiorilli R, De Felice F, Nazzaro M, Giulivi A, Alborino D, Azzellino A, Violini RRandomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). <i>J Am Coll Cardiol 2007;49:1924-30</i> [PMID 17498576] </p> <p> <b>SESAMI, 2007 : </b> Violini R, Musto C, De Felice F, Nazzaro MS, Cifarelli A, Petitti T, Fiorilli RMaintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Stents in Patients With ST-Segment Elevation Myocardial Infarction 3-Year Results of the SESAMI (Sirolimus-Eluting Stent Versus Bare-Metal Stent In Acute Myocardial Infarction) Trial. <i>J Am Coll Cardiol 2010 Feb 23;55:810-814</i> [PMID 20170821] 10.1016/j.jacc.2009.09.046 </p> <p> <b>DECODE, 2005 : </b> Chan C, Zambahari R, Kaul U, Cohen SA, Buchbinder M.Outcomesin diabetic patients with multivessel disease and long lesions: resultsfrom the DECODE study <i>Am J Cardiol 2005; 96 (suppl 7A): 31H</i> [PMID ] </p> <p> <b>SCORPIUS, 2007 : </b> Baumgart D.One year results of the SCORPIUS-Trial - a Germanmulticenter investigation on the eff ectiveness of sirolimus-elutingstents in diabetic patients <i>Annual Scientifi c Meeting of theTranscatheter Cardiovascular Therapeutics. Washington, DC;Oct 2227, 2006. Abstract 288.</i> [PMID ] </p> <p> <b>SCORPIUS, 2007 : </b> Baumgart D, Klauss V, Baer F, Hartmann F, Drexler H, Motz W, Klues H, Hofmann S, Vlker W, Pfannebecker T, Stoll HP, Nickenig GOne-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. <i>J Am Coll Cardiol 2007 Oct 23;50:1627-34</i> [PMID 17950142] </p> <p> <b>MISSION, 2008 : </b> van der Hoeven BL, Liem S, Jukema JW, et al.Prospectiverandomised trial to evaluate the effi cacy and safety of drug-elutingstents versus barem-metal stents for the treatment of acutemyocardial infarction (the MISSION! intervention study) <i>AnnualScientifi c Meeting of the American Heart Association. Chicago, IL,USA; Nov 1215, 2006.</i> [PMID ] </p> <p> <b>MISSION, 2008 : </b> van der Hoeven BL, Liem SS, Jukema JW, Suraphakdee N, Putter H, Dijkstra J, Atsma DE, Bootsma M, Zeppenfeld K, Oemrawsingh PV, van der Wall EE, Schalij MJSirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. <i>J Am Coll Cardiol 2008 Feb 12;51:618-26</i> [PMID 18261680] </p> <p> <b>Ortolani et al, 2007 : </b> Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, Aquilina M, Baldazzi F, Silenzi S, Cooke RM, Reggiani ML, Branzi ARandomized comparative trial of a thin-strut bare metal cobalt-chromium stent versus a sirolimus-eluting stent for coronary revascularization. <i>Catheter Cardiovasc Interv 2007;69:790-8</i> [PMID 17290437] </p> <p> <b>TAXi, 2005 : </b> Goy JJ, Stauffer JC, Siegenthaler M, Benot A, Seydoux CA prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial. <i>J Am Coll Cardiol 2005;45:308-11</i> [PMID 15653032] </p> <p> <b>TAXi, 2005 : </b> Berger A, Stauffer JC, Seydoux C, Siegenthaler M, Benot A, Goy JJThree-year follow-up of the first prospective randomized comparison between paclitaxel and sirolimus stents: the TAXi-LATE trial. <i>Catheter Cardiovasc Interv 2007 Aug 1;70:163-6</i> [PMID 17630653] </p> <p> <b>ISAR-DESIRE (SES vs PES), 2005 : </b> Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig ASirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. <i>JAMA 2005;293:165-71</i> [PMID 15644543] </p> <p> <b>ISAR-DIABETES, 2005 : </b> Dibra A, Kastrati A, Mehilli J, Pache J, Schhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schmig APaclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. <i>N Engl J Med 2005;353:663-70</i> [PMID 16105990] </p> <p> <b>SIRTAX (Windecker), 2005 : </b> Windecker S, Remondino A, Eberli FR, Jni P, Rber L, Wenaweser P, Togni M, Billinger M, Tller D, Seiler C, Roffi M, Corti R, Stsch G, Maier W, Lscher T, Hess OM, Egger M, Meier BSirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. <i>N Engl J Med 2005;353:653-62</i> [PMID 16105989] </p> <p> <b>CORPAL, 2005 : </b> de Lezo J, Medina A, Pan M, et al.de Lezo J, Medina A, Pan M, et al. Drug-eluting stent for complexlesions: latest angiographic data from randomized rapamycinversus paclitaxel CORPAL study <i>J Am Coll Cardiol 2005; 45: 75A.</i> [PMID ] </p> <p> <b>REALITY, 2006 : </b> Morice MC, Colombo A, Meier B, Serruys P, Tamburino C, Guagliumi G, Sousa E, Stoll HPSirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial. <i>JAMA 2006;295:895-904</i> [PMID 16493102] </p> <p> <b>ISAR-SMART 3, 2006 : </b> Mehilli J, Dibra A, Kastrati A, Pache J, Dirschinger J, Schmig ARandomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. <i>Eur Heart J 2006;27:260-6</i> [PMID 16401670] </p> <p> <b>Zhang (SES vs PES), 2006 : </b> Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Ni J, Fang YH, Zhang X, Shen WFOne-year clinical outcomes of Chinese sirolimus-eluting stent in the treatment of unselected patients with coronary artery disease. <i>Chin Med J (Engl) 2006;119:165-8</i> [PMID 16455001] </p> <p> <b>LONG DES II, 2006 : </b> Kim YH, Park SW, Lee SW, Park DW, Yun SC, Lee CW, Hong MK, Kim HS, Ko JK, Park JH, Lee JH, Choi SW, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Park SJSirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. <i>Circulation 2006;114:2148-53</i> [PMID 17060388] </p> <p> <b>PROSIT, 2006 : </b> Lee JH, Kim HS, Lee SW, et al.Prospective randomized trial of asirolimus eluting versus a paclitaxel eluting stent for the treatmentof acute ST-elevation myocardial infarction <i>Annual Scientifi cMeeting of the American College of Cardiology; Atlanta, GA, USA;March 1114, 2006.</i> [PMID ] </p> <p> <b>PROSIT, 2006 : </b> Kornowski RDrug-eluting stents in ST elevation myocardial infarction: In light of the PROSIT trial. <i>Catheter Cardiovasc Interv 2008 Jul 1;72:33-5</i> [PMID 18561153] </p> <p> <b>PROSIT, 2006 : </b> Lee JH, Kim HS, Lee SW, Park JH, Choi SW, Jeong JO, Cho Y, Lee N, Rhee KS, Ko JK, Seong IWProspective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial. <i>Catheter Cardiovasc Interv 2008 Jul 1;72:25-32</i> [PMID 18412270] </p> <p> <b>SORT OUT II, 2008 : </b> Galloe AM.prospective multi-center, large-scale, randomized trialof paclitaxel- and sirolimus-eluting stents in real-world lesions <i>Annual Scientifi c Meeting of the Transcatheter CardiovascularTherapeutics; Washington, DC; Oct 2227, 2006</i> [PMID ] </p> <p> <b>SORT OUT II, 2008 : </b> Galle AM, Thuesen L, Kelbaek H, Thayssen P, Rasmussen K, Hansen PR, Bligaard N, Saunamki K, Junker A, Aare J, Abildgaard U, Ravkilde J, Engstrm T, Jensen JS, Andersen HR, Btker HE, Galatius S, Kristensen SD, Madsen JK, Krusell LR, Abildstrm SZ, StepComparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SORT OUT II randomized trial. <i>JAMA 2008;299:409-16</i> [PMID 18230778] </p> <p> <b>Cervinka, 2006 : </b> Cervinka P, Costa MA, Angiolillo DJ, Spacek R, Bystron M, Kvasnk M, Veselka J, Nanda H, Futamatsu H, Futamatsu K"Head-to-head comparison between sirolimus-eluting and paclitaxel-eluting stents in patients with complex coronary artery disease: an intravascular ultrasound study". <i>Catheter Cardiovasc Interv 2006;67:846-51</i> [PMID 16683273] </p> <p> <b>Petronio et al, 2007 : </b> Petronio AS, De Carlo M, Branchitta G, Papini B, Ciabatti N, Gistri R, Cortese B, Gherarducci G, Barsotti ARandomized comparison of sirolimus and paclitaxel drug-eluting stents for long lesions in the left anterior descending artery: an intravascular ultrasound study. <i>J Am Coll Cardiol 2007;49:539-46</i> [PMID 17276176] </p> <p> <b>Han, 2006 : </b> Han YL, Wang XZ, Jing QM, Wang SL, Ma YY, Luan B[Comparison of Rapamycin and Paclitaxel eluting stent in patients with multi-vessel coronary disease] <i>Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:123-6</i> [PMID 16626577] </p> <p> <b>BASKET (vs paclitaxel), 2005 : </b> Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer MEIncremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitts Trial (BASKET). <i>Lancet 2005;366:921-9</i> [PMID 16154019] </p> <p> <b>Di Lorenzo et al., 2005 : </b> Di Lorenzo E, Varricchio A, Lanzillo T, et al.Paclitaxel and sirolimusstent implantation in patients with acute myocardial infarction (abstr) <i>Circulation 2005;112:U538</i> [PMID ] </p> <p> <b>Stone pooled analysis sirolimus, 2007 : </b> Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MBSafety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. <i>N Engl J Med 2007;356:998-1008</i> [PMID 17296824] </p> <p> <b>Stone pooled analysis TAXUS studies, 2007 : </b> Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MBSafety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. <i>N Engl J Med 2007;356:998-1008</i> [PMID 17296824] </p> <p> <b>Spaulding pooled analysis Ravel Sirius studies, 2007 : </b> Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PWA pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. <i>N Engl J Med 2007;356:989-97</i> [PMID 17296825] </p> <p> <b>ENDEAVOR II, 2006 : </b> Gruberg L.ENDEAVOR II. A randomized comparison of the Endeavor ABT-578 drug-eluting stent with a bare metal stent for coronary revascularization,powerpo <i>http://www.medscape.com/viewarticle/501475</i> [PMID ] </p> <p> <b>ENDEAVOR II, 2006 : </b> Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RERandomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. <i>Circulation 2006 Aug 22;114:798-806</i> [PMID 16908773] </p> <p> <b>ENDEAVOR II, 2006 : </b> Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Mnzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RERandomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions. Clinical and angiographic results of the ENDEAVOR II Trial. <i>Minerva Cardioangiol 2007 Feb;55:1-18</i> [PMID 17287679] </p> <p> <b>ENDEAVOR II, 2006 : </b> Sakurai R, Hongo Y, Yamasaki M, Honda Y, Bonneau HN, Yock PG, Cutlip D, Popma JJ, Zimetbaum P, Fajadet J, Kuntz RE, Wijns W, Fitzgerald PJDetailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). <i>Am J Cardiol 2007 Sep 1;100:818-23</i> [PMID 17719326] </p> <p> <b>ENDEAVOR II, 2006 : </b> Eisenstein EL, Wijns W, Fajadet J, Mauri L, Edwards R, Cowper PA, Kong DF, Anstrom KJLong-Term Clinical and Economic Analysis of the Endeavor Drug-Eluting Stent Versus the Driver Bare-Metal Stent 4-Year Results From the ENDEAVOR II Trial (Randomized Controlled Trial to Evaluate the Safety and Efficacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1178-87</i> [PMID 20129543] 10.1016/j.jcin.2009.10.011 </p> <p> <b>ABSORB, 0 : </b> Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof SA bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. <i>Lancet 2008 Mar 15;371:899-907</i> [PMID 18342684] </p> <p> <b>Pasceri, 2003 : </b> Pasceri V, Granatelli A, Pristipino C, et al.A randomized trial of arapamycin-eluting stent in acute myocardial infarction: preliminaryresults <i>TCT 2003. Am J Cardiol 2003;92(Suppl 6A):1L.</i> [PMID ] </p> <p> <b>STRATEGY, 2005 : </b> Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carri D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode CSirolimus-eluting versus uncoated stents in acute myocardial infarction. <i>N Engl J Med 2006;355:1093-104</i> [PMID 16971716] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Percoco G, Malagutti P, Campo G, Ferrari F, Barbieri D, Cicchitelli G, McFadden EP, Merlini F, Ansani L, Guardigli G, Bettini A, Parrinello G, Boersma E, Ferrari RTirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. <i>JAMA 2005 May 4;293:2109-17</i> [PMID 15870414] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Campo G, Arcozzi C, Malagutti P, Carletti R, Ferrari F, Barbieri D, Parrinello G, Percoco G, Ferrari RTwo-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. <i>J Am Coll Cardiol 2007;50:138-45</i> [PMID 17616297] </p> <p> <b>STRATEGY, 2005 : </b> Valgimigli M, Mittmann N, Cohen DJ, Campo G, Isogai PK, Seung SJ, Dulisse B, Arcozzi C, Squasi P, Percoco G, Ferrari R, A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. <i>Int J Cardiol 2008;128:53-61.</i> [PMID 17698218] 10.1016/j.ijcard.2007.05.021 </p> <p> <b>SPIRIT I, 2005 : </b> Serruys PW, Ong AT, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher A, Grube E, Haase J, Thuesen L, Hamm C, Otto-Terlouw PCA randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. <i>EuroIntervention 2005 May;1:58-65</i> [PMID 19758878] </p> <p> <b>SPIRIT I, 2005 : </b> Tsuchida K, Piek JJ, Neumann FJ, van der Giessen WJ, Wiemer M, Zeiher AM, Grube E, Haase J, Thuesen L, Hamm CW, Veldhof S, Dorange C, Serruys PWOne-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). <i>EuroIntervention 2005 Nov;1:266-72</i> [PMID 19758915] </p> <p> <b>SPIRIT I, 2005 : </b> Tsuchida K, Garca-Garca HM, Ong AT, Valgimigli M, Aoki J, Rademaker TA, Morel MA, van Es GA, Bruining N, Serruys PWRevisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: analysis from the SPIRIT FIRST trial. <i>Catheter Cardiovasc Interv 2006 Feb;67:188-97</i> [PMID 16400664] </p> <p> <b>PERSEUS Workhorse, 2010 : </b> Allocco DJ, Cannon LA, Britt A, Heil JE, Nersesov A, Wehrenberg S, Dawkins KD, Kereiakes DJA prospective evaluation of the safety and efficacy of the TAXUS Element paclitaxel-eluting coronary stent system for the treatment of de novo coronary artery lesions: design and statistical methods of the PERSEUS clinical program. <i>Trials 2010 Jan 7;11:1</i> [PMID 20059766] </p> <p> <b>PERSEUS Workhorse, 2010 : </b> Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA, Hester A, Pitt BCardiovascular events during differing hypertension therapies in patients with diabetes. <i>J Am Coll Cardiol 2010;56:77-85</i> [PMID 20620720] 10.1016/j.jacc.2010.02.046 </p> <p> <b>LEADERS, 2008 : </b> Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, Lenk K, Ischinger T, Klauss V, Eberli F, Corti R, Wijns W, Morice MC, di Mario C, Davies S, van Geuns RJ, Eerdmans P, van Es GA, Meier B, Jni PBiolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet 2008 Aug 31;:</i> [PMID 18765162] </p> <p> <b>GISSOC II, 2010 : </b> Rubartelli P, Petronio AS, Guiducci V, Sganzerla P, Bolognese L, Galli M, Sheiban I, Chirillo F, Ramondo A, Bellotti SComparison of sirolimus-eluting and bare metal stent for treatment of patients with total coronary occlusions: results of the GISSOC II-GISE multicentre randomized trial. <i>Eur Heart J 2010;:</i> [PMID 20566487] 10.1093/eurheartj/ehq199 </p> <p> <b>SPIRIT II, 2006 : </b> Garg S, Serruys P, Onuma Y, Dorange C, Veldhof S, Miquel-Hébert K, Sudhir K, Boland J, Huber K, Garcia E, Te Riele JA3-Year Clinical Follow-Up of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions The SPIRIT II Trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1190-8</i> [PMID 20129545] 10.1016/j.jcin.2009.10.002 </p> <p> <b>SPIRIT II, 2006 : </b> Onuma Y, Tanimoto S, Ruygrok P, Neuzner J, Piek JJ, Seth A, Schofer JJ, Richardt G, Wiemer M, Carrié D, Thuesen L, Dorange C, Miquel-Hebert K, Veldhof S, Serruys PWEfficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: two-year angiographic and three-year clinical results from the SPIRIT II study. <i>Catheter Cardiovasc Interv 2010;76:634-42</i> [PMID 20690152] 10.1002/ccd.22541 </p> <p> <b>SYNTAX, 2009 : </b> Lee TH, Hillis LD, Nabel EGCABG vs. stenting--clinical implications of the SYNTAX trial. <i>N Engl J Med 2009 Feb 19;360:e10</i> [PMID 19228613] 10.1056/NEJMp0900462 </p> <p> <b>SYNTAX, 2009 : </b> Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FWPercutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. <i>N Engl J Med 2009 Mar 5;360:961-72</i> [PMID 19228612] 10.1056/NEJMoa0804626 </p> <p> <b>SYNTAX, 2009 : </b> Banning AP, Westaby S, Morice MC, Kappetein AP, Mohr FW, Berti S, Glauber M, Kellett MA, Kramer RS, Leadley K, Dawkins KD, Serruys PWDiabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. <i>J Am Coll Cardiol 2010;55:1067-75</i> [PMID 20079596] 10.1016/j.jacc.2009.09.057 </p> <p> <b>ENDEAVOR III, 2006 : </b> Miyazawa A, Ako J, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AH, Kandzari DE, Honda Y, Fitzgerald PJ, , Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. <i>Am Heart J 2008;155:108-13.</i> [PMID 18082499] 10.1016/j.ahj.2007.08.008 </p> <p> <b>ENDEAVOR III, 2006 : </b> Kandzari DE, Leon MB, Popma JJ, Fitzgerald PJ, O'Shaughnessy C, Ball MW, Turco M, Applegate RJ, Gurbel PA, Midei MG, Badre SS, Mauri L, Thompson KP, LeNarz LA, Kuntz REComparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. <i>J Am Coll Cardiol 2006;48:2440-7</i> [PMID 17174180] </p> <p> <b>ENDEAVOR III, 2006 : </b> Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJLong-Term Clinical and Economic Analysis of the Endeavor Zotarolimus-Eluting Stent Versus the Cypher Sirolimus-Eluting Stent 3-Year Results From the ENDEAVOR III Trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1199-207</i> [PMID 20129546] 10.1016/j.jcin.2009.10.009 </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MBEndeavor Clinical Program Overview, <i> FDA Advisory Panel, October 10th, 2007</i> [PMID ] </p> <p> <b>ENDEAVOR IV, 2009 : </b> Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJIntravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. <i>JACC Cardiovasc Interv 2009 Aug;2:779-84</i> [PMID 19695548] </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS Jr, Popma JJLate Safety, Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). <i>JACC Cardiovasc Interv 2009 Dec;2:1208-18</i> [PMID 20129547] 10.1016/j.jcin.2009.10.008 </p> <p> <b>ENDEAVOR IV, 2009 : </b> Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DEImproved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. <i>JACC Cardiovasc Interv 2010;3:1043-50</i> [PMID 20965463] 10.1016/j.jcin.2010.07.008 </p> <p> <b>SPIRIT IV, 2010 : </b> Nikolsky E, Lansky AJ, Sudhir K, Doostzadeh J, Cutlip DE, Piana R, Su X, White R, Simonton CA, Stone GWSPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. <i>Am Heart J 2009;158:520-526.e2</i> [PMID 19781409] </p> <p> <b>SPIRIT IV, 2010 : </b> Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJEverolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. <i>N Engl J Med 2010 May 6;362:1663-74</i> [PMID 20445180] 10.1056/NEJMoa0910496 </p> <p> <b>SPIRIT IV, 2010 : </b> Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GWOutcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). <i>J Am Coll Cardiol 2010;56:2084-9</i> [PMID 21144968] 10.1016/j.jacc.2010.10.006 </p> <p> <b>SPIRIT III, 2008 : </b> Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ, , Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. <i>JAMA 2008;299:1903-13.</i> [PMID 18430909] 10.1001/jama.299.16.1903 </p> <p> <b>SPIRIT III, 2008 : </b> Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Caputo R, Xenopoulos N, Applegate R, Gordon P, White RM, Sudhir K, Cutlip DE, Petersen JL <i>Circulation 2009;119:680-6</i> [PMID 19171853] </p> <p> <b>SPIRIT III, 2008 : </b> Applegate RJ, Hermiller JJ, Sanz M, Doostzadeh J, Pierson W, Su X, Lansky AJ, Sudhir K, Stone GWComparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients with two treated vessels: 2-year results from the SPIRIT III randomised trial. <i>EuroIntervention 2010;6:437-46</i> [PMID 20884430] 10.4244/EIJ30V6I4A75 </p> <p> <b>ISAR-TEST-1, 2006 : </b> Mehilli J, Kastrati A, Wessely R, Dibra A, Hausleiter J, Jaschke B, Dirschinger J, Schmig ARandomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. <i>Circulation 2006;113:273-9</i> [PMID 16391155] </p> <p> <b>ISAR-LEFT-MAIN, 2009 : </b> Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig APaclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease. <i>J Am Coll Cardiol 2009 May 12;53:1760-8</i> [PMID 19422982] </p> <p> <b>ZoMaxx phase 3, 2007 : </b> Abizaid A, Lansky AJ, Fitzgerald PJ, Tanajura LF, Feres F, Staico R, Mattos L, Abizaid A, Chaves A, Centemero M, Sousa AG, Sousa JE, Zaugg MJ, Schwartz LBPercutaneous coronary revascularization using a trilayer metal phosphorylcholine-coated zotarolimus-eluting stent. <i>Am J Cardiol 2007 May 15;99:1403-8</i> [PMID 17493469] </p> <p> <b>RESEARCH à effacer, 2004 : </b> Lemos PA, Hoye A, Goedhart D, Arampatzis CA, Saia F, van der Giessen WJ, McFadden E, Sianos G, Smits PC, Hofma SH, de Feyter PJ, van Domburg RT, Serruys PWClinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. <i>Circulation 2004;109:1366-70</i> [PMID 14993127] </p> <p> <b>PRISON III, 2007 : </b> Suttorp MJ, Laarman GJA randomized comparison of sirolimus-eluting stent implantation with zotarolimus-eluting stent implantation for the treatment of total coronary occlusions: rationale and design of the PRImary Stenting of Occluded Native coronary arteries III (PRISON III) study. <i>Am Heart J 2007 Sep;154:432-5</i> [PMID 17719285] </p> <p> <b>ZEST (vs SES), 2009 : </b> Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJComparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial. <i>J Am Coll Cardiol 2010 Oct 5;56:1187-95</i> [PMID 20883925] 10.1016/j.jacc.2010.03.086 </p> <p> <b>ZEST AMI (vs PES), 2009 : </b> Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJComparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. <i>Am J Cardiol 2009;104:1370-6</i> [PMID 19892052] </p> <p> <b>ISAR, 2005 : </b> Hausleiter J, Kastrati A, Wessely R, Dibra A, Mehilli J, Schratzenstaller T, Graf I, Renke-Gluszko M, Behnisch B, Dirschinger J, Wintermantel E, Schmig APrevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating. <i>Eur Heart J 2005;26:1475-81</i> [PMID 15975990] </p> <p> <b>Dakik, 1998 : </b> Dakik HA, Kleiman NS, Farmer JA, He ZX, Wendt JA, Pratt CM, Verani MS, Mahmarian JJIntensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study <i>Circulation 1998;98:2017-23</i> [PMID 9808599] </p> <p> <b>ALKK, 2003 : </b> Zeymer U, Uebis R, Vogt A, Glunz HG, Vöhringer HF, Harmjanz D, Neuhaus KLRandomized comparison of percutaneous transluminal coronary angioplasty and medical therapy in stable survivors of acute myocardial infarction with single vessel disease: a study of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzte <i>Circulation 2003;108:1324-8</i> [PMID 12939210] 10.1161/01.CIR.0000087605.09362.0E </p> <p> <b>Hambrecht, 2004 : </b> Hambrecht R, Walther C, Möbius-Winkler S, Gielen S, Linke A, Conradi K, Erbs S, Kluge R, Kendziorra K, Sabri O, Sick P, Schuler GPercutaneous coronary angioplasty compared with exercise training in patients with stable coronary artery disease: a randomized trial <i>Circulation 2004;109:1371-8</i> [PMID 15007010] 10.1161/01.CIR.0000121360.31954.1F </p> <p> <b>Bech, 2001 : </b> Bech GJ, De Bruyne B, Pijls NH, de Muinck ED, Hoorntje JC, Escaned J, Stella PR, Boersma E, Bartunek J, Koolen JJ, Wijns WFractional flow reserve to determine the appropriateness of angioplasty in moderate coronary stenosis: a randomized trial <i>Circulation 2001;103:2928-34</i> [PMID 11413082] </p> <p> <b>ARTS, 2001 : </b> Abizaid A, Costa MA, Centemero M, Abizaid AS, Legrand VM, Limet RV, Schuler G, Mohr FW, Lindeboom W, Sousa AG, Sousa JE, van Hout B, Hugenholtz PG, Unger F, Serruys PWClinical and economic impact of diabetes mellitus on percutaneous and surgical treatment of multivessel coronary disease patients: insights from the Arterial Revascularization Therapy Study (ARTS) trial. <i>Circulation 2001;104:533-8</i> [PMID 11479249] </p> <p> <b>ARTS, 2001 : </b> de Feyter PJ, Serruys PW, Unger F, Beyar R, de Valk V, Milo S, Simon R, Regensburger D, Crean PA, McGovern E, van den Heuvel P, van Cauwelaert C, Penn I, Tyers GF, Lindeboom WBypass surgery versus stenting for the treatment of multivessel disease in patients with unstable angina compared with stable angina. <i>Circulation 2002;105:2367-72</i> [PMID 12021222] </p> <p> <b>ARTS, 2001 : </b> Legrand VM, Serruys PW, Unger F, van Hout BA, Vrolix MC, Fransen GM, Nielsen TT, Paulsen PK, Gomes RS, de Queiroz e Melo JM, Neves JP, Lindeboom W, Backx BThree-year outcome after coronary stenting versus bypass surgery for the treatment of multivessel disease. <i>Circulation 2004;109:1114-20</i> [PMID 14993134] </p> <p> <b>ARTS, 2001 : </b> Serruys PW, Unger F, Sousa JE, Jatene A, Bonnier HJ, Schönberger JP, Buller N, Bonser R, van den Brand MJ, van Herwerden LA, Morel MA, van Hout BAComparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease. <i>N Engl J Med 2001;344:1117-24</i> [PMID 11297702] </p> <p> <b>ARTS, 2001 : </b> Unger F, Serruys PW, Yacoub MH, Ilsley C, Paulsen PK, Nielsen TT, Eysmann L, Kiemeneij FRevascularization in multivessel disease: comparison between two-year outcomes of coronary bypass surgery and stenting. <i>J Thorac Cardiovasc Surg 2003;125:809-20</i> [PMID 12698143] </p> <p> <b>Diegeler, 2002 : </b> Diegeler A, Thiele H, Falk V, Hambrecht R, Spyrantis N, Sick P, Diederich KW, Mohr FW, Schuler GComparison of stenting with minimally invasive bypass surgery for stenosis of the left anterior descending coronary artery. <i>N Engl J Med 2002;347:561-6</i> [PMID 12192015] </p> <p> <b>Diegeler, 2002 : </b> Diegeler A, Spyrantis N, Matin M, Falk V, Hambrecht R, Autschbach R, Mohr FW, Schuler GThe revival of surgical treatment for isolated proximal high grade LAD lesions by minimally invasive coronary artery bypass grafting. <i>Eur J Cardiothorac Surg 2000;17:501-4</i> [PMID 10814909] </p> <p> <b>Drenth, 2002 : </b> Drenth DJ, Veeger NJ, Grandjean JG, Mariani MA, van Boven AJ, Boonstra PWIsolated high-grade lesion of the proximal LAD: a stent or off-pump LIMA? <i>Eur J Cardiothorac Surg 2004;25:567-71</i> [PMID 15037273] </p> <p> <b>Drenth, 2002 : </b> Drenth DJ, Veeger NJ, Winter JB, Grandjean JG, Mariani MA, Boven van AJ, Boonstra PWA prospective randomized trial comparing stenting with off-pump coronary surgery for high-grade stenosis in the proximal left anterior descending coronary artery: three-year follow-up. <i>J Am Coll Cardiol 2002;40:1955-60</i> [PMID 12475455] </p> <p> <b>Drenth, 2002 : </b> Drenth DJ, Winter JB, Veeger NJ, Monnink SH, van Boven AJ, Grandjean JG, Mariani MA, Boonstra PWMinimally invasive coronary artery bypass grafting versus percutaneous transluminal coronary angioplasty with stenting in isolated high-grade stenosis of the proximal left anterior descending coronary artery: six months' angiographic and clinical follow-up of a prospective randomized study. <i>J Thorac Cardiovasc Surg 2002;124:130-5</i> [PMID 12091818] </p> <p> <b>ERACI II, 2003 : </b> Rodriguez A, Bernardi V, Navia J, Baldi J, Grinfeld L, Martinez J, Vogel D, Grinfeld R, Delacasa A, Garrido M, Oliveri R, Mele E, Palacios I, O'Neill WArgentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators. <i>J Am Coll Cardiol 2001;37:51-8</i> [PMID 11153772] </p> <p> <b>ERACI II, 2003 : </b> Rodriguez A, Rodríguez Alemparte M, Baldi J, Navia J, Delacasa A, Vogel D, Oliveri R, Fernández Pereira C, Bernardi V, O'Neill W, Palacios IFCoronary stenting versus coronary bypass surgery in patients with multiple vessel disease and significant proximal LAD stenosis: results from the ERACI II study. <i>Heart 2003;89:184-8</i> [PMID 12527674] </p> <p> <b>Grip, 2001 : </b> Grip L, Wahrborg P, Odell A, Albertsson P, Berglin E, Brandrup-Coronary artery bypass beating heart surgery with LIMA graft, versus coronary angioplasty with stent for patients with single left anterior descending artery - a pilot study <i>European Heart Journal 2001;22 (Suppl):597</i> [PMID ] </p> <p> <b>OCTOSTENT, 2003 : </b> Eefting F, Nathoe H, van Dijk D, Jansen E, Lahpor J, Stella P, Suyker W, Diephuis J, Suryapranata H, Ernst S, Borst C, Buskens E, Grobbee D, de Jaegere PRandomized comparison between stenting and off-pump bypass surgery in patients referred for angioplasty. <i>Circulation 2003;108:2870-6</i> [PMID 14656913] </p> <p> <b>OCTOSTENT, 2003 : </b> van Dijk D, Nierich AP, Eefting FD, Buskens E, Nathoe HM, Jansen EW, Borst C, Knape JT, Bredée JJ, Robles de Medina EO, Grobbee DE, Diephuis JC, de Jaegere PPThe Octopus Study: rationale and design of two randomized trials on medical effectiveness, safety, and cost-effectiveness of bypass surgery on the beating heart. <i>Control Clin Trials 2000;21:595-609</i> [PMID 11146152] </p> <p> <b>SIMA, 2000 : </b> Goy JJ, Kaufmann U, Goy-Eggenberger D, Garachemani A, Hurni M, Carrel T, Gaspardone A, Burnand B, Meier B, Versaci F, Tomai F, Bertel O, Pieper M, de Benedictis M, Eeckhout EA prospective randomized trial comparing stenting to internal mammary artery grafting for proximal, isolated de novo left anterior coronary artery stenosis: the SIMA trial. Stenting vs Internal Mammary Artery. <i>Mayo Clin Proc 2000;75:1116-23</i> [PMID 11075740] </p> <p> <b>SOS, 2002 : </b> Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery trial): a randomised controlled trial. <i>Lancet 2002;360:965-70</i> [PMID 12383664] </p> <p> <b>SOS, 2002 : </b> Stables RHDesign of the 'Stent or Surgery' trial (SoS): a randomized controlled trial to compare coronary artery bypass grafting with percutaneous transluminal coronary angioplasty and primary stent implantation in patients with multi-vessel coronary artery disease. <i>Semin Interv Cardiol 1999;4:201-7</i> [PMID 10738353] </p> <p> <b>SOS, 2002 : </b> Zhang Z, Mahoney EM, Stables RH, Booth J, Nugara F, Spertus JA, Weintraub WSDisease-specific health status after stent-assisted percutaneous coronary intervention and coronary artery bypass surgery: one-year results from the Stent or Surgery trial. <i>Circulation 2003;108:1694-700</i> [PMID 12975252] </p> <p> <b>SOS, 2002 : </b> Zhang Z, Weintraub WS, Mahoney EM, Spertus JA, Booth J, Nugara F, Stables RH, Vaccarino VRelative benefit of coronary artery bypass grafting versus stent-assisted percutaneous coronary intervention for angina pectoris and multivessel coronary disease in women versus men (one-year results from the Stent or Surgery trial). <i>Am J Cardiol 2004;93:404-9</i> [PMID 14969611] </p> <p> <b>SOS, 2002 : </b> Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RHRandomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). <i>Circulation 2008;118:381-8</i> [PMID 18606919] </p> <p> <b>SOS, 2002 : </b> Booth J, Clayton T, Pepper J, Nugara F, Flather M, Sigwart U, Stables RHRandomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the Stent or Surgery Trial (SoS). <i>Circulation 2008 Jul 22;118:381-8</i> [PMID 18606919] </p> <p> <b>CARDia (PCI), 2008 : </b> Kapur A, Hall RJ, Malik IS, Qureshi AC, Butts J, de Belder M, Baumbach A, Angelini G, de Belder A, Oldroyd KG, Flather M, Roughton M, Nihoyannopoulos P, Bagger JP, Morgan K, Beatt KJRandomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. <i>J Am Coll Cardiol 2010 Feb 2;55:432-40</i> [PMID 20117456] 10.1016/j.jacc.2009.10.014 </p> <p> <b>AMIST (Reeves), 2004 : </b> Reeves BC, Angelini GD, Bryan AJ, Taylor FC, Cripps T, Spyt TJ, Samani NJ, Roberts JA, Jacklin P, Seehra HK, Culliford LA, Keenan DJ, Rowlands DJ, Clarke B, Stanbridge R, Foale RA multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. <i>Health Technol Assess 2004;8:1-43</i> [PMID 15080865] </p> <p> <b>Hong, 2005 : </b> Hong SJ, Lim DS, Seo HS, Kim YH, Shim WJ, Park CG, Oh DJ, Ro YMPercutaneous coronary intervention with drug-eluting stent implantation vs. minimally invasive direct coronary artery bypass (MIDCAB) in patients with left anterior descending coronary artery stenosis. <i>Catheter Cardiovasc Interv 2005;64:75-81</i> [PMID 15619278] </p> <p> <b>Kim, 2005 : </b> Kim JW, Lim DS, Sun K, Shim WJ, Rho YMStenting or MIDCAB using ministernotomy for revascularization of proximal left anterior descending artery? <i>Int J Cardiol 2005;99:437-41</i> [PMID 15771925] </p> <p> <b>Costar II, 2008 : </b> Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns WA novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. <i>J Am Coll Cardiol 2008 Apr 22;51:1543-52</i> [PMID 18420096] </p> <p> <b>Costar II, 2008 : </b> Kereiakes DJ, Petersen JL, Batchelor WB, Fitzgerald PJ, Mehran R, Lansky A, Tsujino I, Schofer J, Dubois C, Verheye S, Cristea E, Garg J, Wijns W, Krucoff MWClinical and angiographic outcomes in diabetic patients following single or multivessel stenting in the COSTAR II randomized trial. <i>J Invasive Cardiol 2008;20:335-41</i> [PMID 18599890] </p> <p> <b>Schofield, 1999 : </b> Schofield PM, Sharples LD, Caine N, Burns S, Tait S, Wistow T, Buxton M, Wallwork JTransmyocardial laser revascularisation in patients with refractory angina: a randomised controlled trial. <i>Lancet 1999 Feb 13;353:519-24</i> [PMID 10028979] </p> <p> <b>Schofield, 1999 : </b> Campbell HE, Tait S, Buxton MJ, Sharples LD, Caine N, Schofield PM, Wallwork JA UK trial-based cost--utility analysis of transmyocardial laser revascularization compared to continued medical therapy for treatment of refractory angina pectoris. <i>Eur J Cardiothorac Surg 2001;20:312-8</i> [PMID 11463549] </p> <p> <b>Allen, 1999 : </b> Allen KB, Dowling RD, Fudge TL, Schoettle GP, Selinger SL, Gangahar DM, Angell WW, Petracek MR, Shaar CJ, O'Neill WWComparison of transmyocardial revascularization with medical therapy in patients with refractory angina. <i>N Engl J Med 1999;341:1029-36</i> [PMID 10502592] </p> <p> <b>Allen, 1999 : </b> Allen KB, Dowling RD, Angell WW, Gangahar DM, Fudge TL, Richenbacher W, Selinger SL, Petracek MR, Murphy DTransmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. <i>Ann Thorac Surg 2004;77:1228-34</i> [PMID 15063241] </p> <p> <b>Allen, 1999 : </b> Allen KB, Dowling RD, DelRossi AJ, Realyvasques F, Lefrak EA, Pfeffer TA, Fudge TL, Mostovych M, Schuch D, Szentpetery S, Shaar CJTransmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial. <i>J Thorac Cardiovasc Surg 2000;119:540-9</i> [PMID 10694615] </p> <p> <b>Allen, 1999 : </b> Allen KB, Dowling RD, Schuch DR, Pfeffer TA, Marra S, Lefrak EA, Fudge TL, Mostovych M, Szentpetery S, Saha SP, Murphy D, Dennis HAdjunctive transmyocardial revascularization: five-year follow-up of a prospective, randomized trial. <i>Ann Thorac Surg 2004;78:458-65; discussion 458-65</i> [PMID 15276496] </p> <p> <b>Frazier, 1999 : </b> Frazier OH, March RJ, Horvath KATransmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. <i>N Engl J Med 1999;341:1021-8</i> [PMID 10502591] </p> <p> <b>Frazier, 1999 : </b> Frazier OH, Tuzun E, Eichstadt H, Boyce SW, Lansing AM, March RJ, Sartori M, Kadipasaoglu KATransmyocardial laser revascularization as an adjunct to coronary artery bypass grafting: a randomized, multicenter study with 4-year follow-up. <i>Tex Heart Inst J 2004;31:231-9</i> [PMID 15562842] </p> <p> <b>Frazier, 1999 : </b> Jones JW, Schmidt SE, Richman BW, Miller CC 3rd, Sapire KJ, Burkhoff D, Baldwin JCHolmium:YAG laser transmyocardial revascularization relieves angina and improves functional status. <i>Ann Thorac Surg 1999;67:1596-601; discussion 1601-2</i> [PMID 10391261] </p> <p> <b>ATLANTIC (Burkhoff), 1999 : </b> Burkhoff D, Schmidt S, Schulman SP, Myers J, Resar J, Becker LC, Weiss J, Jones JWTransmyocardial laser revascularisation compared with continued medical therapy for treatment of refractory angina pectoris: a prospective randomised trial. ATLANTIC Investigators. Angina Treatments-Lasers and Normal Therapies in Comparison. <i>Lancet 1999;354:885-90</i> [PMID 10489946] </p> <p> <b>Aaberge, 2000 : </b> Aaberge L, Nordstrand K, Dragsund M, Saatvedt K, Endresen K, Golf S, Geiran O, Abdelnoor M, Forfang KTransmyocardial revascularization with CO2 laser in patients with refractory angina pectoris. Clinical results from the Norwegian randomized trial. <i>J Am Coll Cardiol 2000;35:1170-7</i> [PMID 10758957] </p> <p> <b>Aaberge, 2000 : </b> Aaberge L, Rootwelt K, Blomhoff S, Saatvedt K, Abdelnoor M, Forfang KContinued symptomatic improvement three to five years after transmyocardial revascularization with CO(2) laser: a late clinical follow-up of the Norwegian Randomized trial with transmyocardial revascularization. <i>J Am Coll Cardiol 2002;39:1588-93</i> [PMID 12020484] </p> <p> <b>Aaberge, 2000 : </b> Aaberge L, Aakhus S, Nordstrand K, Abdelnoor M, Ihlen H, Forfang KMyocardial performance after transmyocardial revascularization with CO(2)laser. A dobutamine stress echocardiographic study. <i>Eur J Echocardiogr 2001;2:187-96</i> [PMID 11882452] </p> <p> <b>Aaberge, 2000 : </b> Aaberge L, Rootwelt K, Smith HJ, Nordstrand K, Forfang KEffects of transmyocardial revascularization on myocardial perfusion and systolic function assessed by nuclear and magnetic resonance imaging methods. <i>Scand Cardiovasc J 2001;35:8-13</i> [PMID 11354578] </p> <p> <b>Huikeshoven, 2003 : </b> Huikeshoven M, van der Sloot JA, Tukkie R, van Gemert MJ, Tijssen JG, Beek JFImproved quality of life after XeCl excimer transmyocardial laser revascularization: results of a randomized trial. <i>Lasers Surg Med 2003;33:1-7</i> [PMID 12866115] </p> <p> <b>Jones (doublons Frazier), 1999 : </b> Jones JW, Schmidt SE, Richman BW, Miller CC 3rd, Sapire KJ, Burkhoff D, Baldwin JCHolmium:YAG laser transmyocardial revascularization relieves angina and improves functional status. <i>Ann Thorac Surg 1999;67:1596-601; discussion 1601-2</i> [PMID 10391261] </p> <p> <b>Jones (doublons Frazier), 1999 : </b> Spertus JA, Jones PG, Coen M, Garg M, Bliven B, O'Keefe J, March RJ, Horvath KTransmyocardial CO(2) laser revascularization improves symptoms, function, and quality of life: 12-month results from a randomized controlled trial. <i>Am J Med 2001;111:341-8</i> [PMID 11583635] </p> <p> <b>PACIFIC, 2000 : </b> Oesterle SN, Sanborn TA, Ali N, Resar J, Ramee SR, Heuser R, Dean L, Knopf W, Schofield P, Schaer GL, Reeder G, Masden R, Yeung AC, Burkhoff DPercutaneous transmyocardial laser revascularisation for severe angina: the PACIFIC randomised trial. Potential Class Improvement From Intramyocardial Channels. <i>Lancet 2000;356:1705-10</i> [PMID 11095257] </p> <p> <b>Galiñanes, 2004 : </b> Galiñanes M, Loubani M, Sensky PR, Hassouna A, Cherryman GR, Leverment JN, Samani NJEfficacy of transmyocardial laser revascularization and thoracic sympathectomy for the treatment of refractory angina. <i>Ann Thorac Surg 2004;78:122-8</i> [PMID 15223416] </p> <p> <b>Stone, 2002 : </b> Stone GW, Teirstein PS, Rubenstein R, Schmidt D, Whitlow PL, Kosinski EJ, Mishkel G, Power JAA prospective, multicenter, randomized trial of percutaneous transmyocardial laser revascularization in patients with nonrecanalizable chronic total occlusions. <i>J Am Coll Cardiol 2002;39:1581-7</i> [PMID 12020483] </p> <p> <b>Allen, 2000 : </b> Allen KB, Dowling RD, DelRossi AJ, Realyvasques F, Lefrak EA, Pfeffer TA, Fudge TL, Mostovych M, Schuch D, Szentpetery S, Shaar CJTransmyocardial laser revascularization combined with coronary artery bypass grafting: a multicenter, blinded, prospective, randomized, controlled trial. <i>J Thorac Cardiovasc Surg 2000;119:540-9</i> [PMID 10694615] </p> <p> <b>Salem, 2004 : </b> Salem M, Rotevatn S, Stavnes S, Brekke M, Vollset SE, Nordrehaug JEUsefulness and safety of percutaneous myocardial laser revascularization for refractory angina pectoris. <i>Am J Cardiol 2004;93:1086-91</i> [PMID 15110197] </p> <p> <b>Loubani, 2003 : </b> Loubani M, Chin D, Leverment JN, Galiñanes MMid-term results of combined transmyocardial laser revascularization and coronary artery bypass. <i>Ann Thorac Surg 2003;76:1163-6</i> [PMID 14530005] </p> <p> <b>van der Sloot, 2004 : </b> van der Sloot JA, Huikeshoven M, Tukkie R, Verberne HJ, van der Meulen J, van Eck-Smit BL, van Gemert MJ, Tijssen JG, Beek JFTransmyocardial revascularization using an XeCl excimer laser: results of a randomized trial. <i>Ann Thorac Surg 2004;78:875-81; discussion 881-2</i> [PMID 15337012] </p> <p> <b>March, 1999 : </b> March RJTransmyocardial laser revascularization with the CO2 laser: one year results of a randomized, controlled trial. <i>Semin Thorac Cardiovasc Surg 1999;11:12-8</i> [PMID 9930706] </p> <p> <b>Leon (high dose), 2005 : </b> Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz REA blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. <i>J Am Coll Cardiol 2005;46:1812-9</i> [PMID 16286164] </p> <p> <b>Gray, 2003 : </b> Gray TJ, Burns SM, Clarke SC, Tait S, Sharples LD, Caine N, Schofield PMPercutaneous myocardial laser revascularization in patients with refractory angina pectoris. <i>Am J Cardiol 2003;91:661-6</i> [PMID 12633794] </p> <p> <b>Zhao, 2006 : </b> Zhao H, Wan F, Guo JX, Chen Y, Xie JY, Yang W, Zhang P[Chronic effects of transmyocardial laser revascularization combined with off-pump coronary artery by pass (OPCAB) compared with OPCAB alone in patients with ischemic heart disease: a prospective multicenter follow-up study] <i>Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:710-3</i> [PMID 17081396] </p> <p> <b>TIME, 2001 : </b> Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. <i>Lancet 2001;358:951-7</i> [PMID 11583747] </p> <p> <b>TIME, 2001 : </b> Masson C, Pruvo JP, Meder JF, Cordonnier C, Touzé E, De La Sayette V, Giroud M, Mas JL, Leys DSpinal cord infarction: clinical and magnetic resonance imaging findings and short term outcome. <i>J Neurol Neurosurg Psychiatry 2004;75:1431-5</i> [PMID 15377691] </p> <p> <b>TIME, 2001 : </b> Pfisterer M, Buser P, Osswald S, Allemann U, Amann W, Angehrn W, Eeckhout E, Erne P, Estlinbaum W, Kuster G, Moccetti T, Naegeli B, Rickenbacher POutcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. <i>JAMA 2003;289:1117-23</i> [PMID 12622581] </p> <p> <b>BASKET-PROVE, 2008 : </b> Pfisterer M, Bertel O, Bonetti PO, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C, , Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design. <i>Am Heart J 2008;155:609-14.</i> [PMID 18371466] 10.1016/j.ahj.2007.11.011 </p> <p> <b>ISAR-DESIRE (SES vs PTCA), 2005 : </b> Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig ASirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. <i>JAMA 2005;293:165-71</i> [PMID 15644543] </p> <p> <b>ISAR-DESIRE (PES vs PTCA), 2005 : </b> Kastrati A, Mehilli J, von Beckerath N, Dibra A, Hausleiter J, Pache J, Schhlen H, Schmitt C, Dirschinger J, Schmig ASirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. <i>JAMA 2005;293:165-71</i> [PMID 15644543] </p> <p> <b>Pan, 2007 : </b> Pan M, Surez de Lezo J, Medina A, Romero M, Delgado A, Segura J, Ojeda S, Mazuelos F, Hernandez E, Melian F, Pavlovic D, Esteban F, Herrador JDrug-eluting stents for the treatment of bifurcation lesions: a randomized comparison between paclitaxel and sirolimus stents. <i>Am Heart J 2007 Jan;153:15.e1-7</i> [PMID 17174630] </p> <p> <b>BARI 2D, 2009 : </b> Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. <i>Am Heart J 2008;156:528-536, 536.e1-5</i> [PMID 18760137] </p> <p> <b>BARI 2D, 2009 : </b> A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease. <i>N Engl J Med 2009;:</i> [PMID 19502645] </p> <p> <b>BARI 2D, 2009 : </b> Chaitman BR, Hardison RM, Adler D, Gebhart S, Grogan M, Ocampo S, Sopko G, Ramires JA, Schneider D, Frye RLThe Bypass Angioplasty Revascularization Investigation 2 Diabetes Randomized Trial of Different Treatment Strategies in Type 2 Diabetes Mellitus With Stable Ischemic Heart Disease. Impact of Treatment Strategy on Cardiac Mortality and Myocardial Infarction. <i>Circulation 2009;:</i> [PMID 19920001] </p> <p> <b>LEMANS, 2002 : </b> Buszman PE, Kiesz SR, Bochenek A, Peszek-Przybyla E, Szkrobka I, Debinski M, Bialkowska B, Dudek D, Gruszka A, Zurakowski A, Milewski K, Wilczynski M, Rzeszutko L, Buszman P, Szymszal J, Martin JL, Tendera MAcute and late outcomes of unprotected left main stenting in comparison with surgical revascularization. <i>J Am Coll Cardiol 2008;51:538-45</i> [PMID 18237682] </p> <p> <b>ZEST AMI (vs SES), 2009 : </b> Lee CW, Park DW, Lee SH, Kim YH, Hong MK, Kim JJ, Park SW, Yun SC, Seong IW, Lee JH, Lee NH, Cho YH, Cheong SS, Lim DS, Yang JY, Lee SG, Kim KS, Yoon J, Jeong MH, Seung KB, Hong TJ, Park SJComparison of the efficacy and safety of zotarolimus-, sirolimus-, and paclitaxel-eluting stents in patients with ST-elevation myocardial infarction. <i>Am J Cardiol 2009;104:1370-6</i> [PMID 19892052] </p> <p> <b>ISAR TEST 2 (vs SES), 2009 : </b> Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati AA polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>Eur Heart J 2009;:</i> [PMID 19240066] </p> <p> <b>ISAR TEST 2 (vs SES), 2009 : </b> Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati AA polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>Eur Heart J 2009;30:923-31</i> [PMID 19240066] </p> <p> <b>ISAR TEST 2 (vs SES), 2009 : </b> Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schömig A, Mehilli J2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. <i>J Am Coll Cardiol 2010 Jun 8;55:2536-43</i> [PMID 20417052] 10.1016/j.jacc.2010.03.020 </p> <p> <b>ISAR TEST 2 (vs ZES), 2009 : </b> Byrne RAISAR-TEST 2: A prospective randomized trial comparing polymer-free rapamycin and probucol-eluting stents, polymer-based sirolimus-eluting stents, and zotarolimus-eluting stents in patients with coronary artery disease. <i>TCT, October 16, 2008.</i> [PMID ] </p> <p> <b>ISAR TEST 2 (vs ZES), 2009 : </b> Byrne RA, Mehilli J, Iijima R, Schulz S, Pache J, Seyfarth M, Schömig A, Kastrati AA polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents. <i>Eur Heart J 2009 Feb 24;:</i> [PMID 19240066] </p> <p> <b>ISAR TEST 2 (vs ZES), 2009 : </b> Byrne RA, Kastrati A, Tiroch K, Schulz S, Pache J, Pinieck S, Massberg S, Seyfarth M, Laugwitz KL, Birkmeier KA, Schömig A, Mehilli J2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. <i>J Am Coll Cardiol 2010 Jun 8;55:2536-43</i> [PMID 20417052] 10.1016/j.jacc.2010.03.020 </p> <p> <b>ACIP, 1997 : </b> Davies RF, Goldberg AD, Forman S, Pepine CJ, Knatterud GL, Geller N, Sopko G, Pratt C, Deanfield J, Conti CRAsymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. <i>Circulation 1997;95:2037-43</i> [PMID 9133513] </p> <p> <b>DANAMI, 2007 : </b> Madsen JK, Nielsen TT, Grande P, Eriksen UH, Saunamäki K, Thayssen P, Kassis E, Rasmussen K, Haunsø S, Haghfelt T, Fritz-Hansen P, Hjelms E, Paulsen PK, Alstrup P, Arendrup H, Niebuhr-Jørgensen U, Andersen LIRevascularization compared to medical treatment in patients with silent vs. symptomatic residual ischemia after thrombolyzed myocardial infarction--the DANAMI study. <i>Cardiology 2007;108:243-51</i> [PMID 17114878] </p> <p> <b>DANAMI, 2007 : </b> Madsen JK, Grande P, Saunamäki K, Thayssen P, Kassis E, Eriksen U, Rasmussen K, Haunsø S, Nielsen TT, Haghfelt T, Fritz-Hansen P, Hjelms E, Paulsen PK, Alstrup P, Arendrup H, Niebuhr-Jørgensen U, Andersen LIDanish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI). DANish trial in Acute Myocardial Infarction. <i>Circulation 1997;96:748-55</i> [PMID 9264478] </p> <p> <b>INSPIRE, 2006 : </b> Mahmarian JJ, Dakik HA, Filipchuk NG, Shaw LJ, Iskander SS, Ruddy TD, Keng F, Henzlova MJ, Allam A, Moyé LA, Pratt CMAn initial strategy of intensive medical therapy is comparable to that of coronary revascularization for suppression of scintigraphic ischemia in high-risk but stable survivors of acute myocardial infarction. <i>J Am Coll Cardiol 2006;48:2458-67</i> [PMID 17174182] </p> <p> <b>SWISSI II, 2007 : </b> Erne P, Schoenenberger AW, Burckhardt D, Zuber M, Kiowski W, Buser PT, Dubach P, Resink TJ, Pfisterer MEffects of percutaneous coronary interventions in silent ischemia after myocardial infarction: the SWISSI II randomized controlled trial. <i>JAMA 2007;297:1985-91</i> [PMID 17488963] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JAFive-year follow-up of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2007 Mar 6;115:1082-9</i> [PMID 17339566] </p> <p> <b>MASS II, 2007 : </b> Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, Pereira AC, Favarato D, Rocha AS, Hueb AC, Ramires JATen-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. <i>Circulation 2010;122:949-57</i> [PMID 20733102] 10.1161/CIRCULATIONAHA.109.911669 </p> <p> <b>VA, 1984 : </b> Eleven-year survival in the Veterans Administration randomized trial of coronary bypass surgery for stable angina. The Veterans Administration Coronary Artery Bypass Surgery Cooperative Study Group. <i>N Engl J Med 1984 Nov 22;311:1333-9</i> [PMID 6333636] </p> <p> <b>VA, 1984 : </b> Parisi AF, Khuri S, Deupree RH, Sharma GV, Scott SM, Luchi RJMedical compared with surgical management of unstable angina. 5-year mortality and morbidity in the Veterans Administration Study. <i>Circulation 1989 Nov;80:1176-89</i> [PMID 2680157] </p> <p> <b>VA, 1984 : </b> Takaro T, Peduzzi P, Detre KM, Hultgren HN, Murphy ML, van der Bel-Kahn J, Thomsen J, Meadows WRSurvival in subgroups of patients with left main coronary artery disease. Veterans Administration Cooperative Study of Surgery for Coronary Arterial Occlusive Disease. <i>Circulation 1982 Jul;66:14-22</i> [PMID 6979435] </p> <p> <b>VA, 1984 : </b> Eighteen-year follow-up in the Veterans Affairs Cooperative Study of Coronary Artery Bypass Surgery for stable angina. The VA Coronary Artery Bypass Surgery Cooperative Study Group. <i>Circulation 1992 Jul;86:121-30</i> [PMID 1617765] </p> <p> <b>VA, 1984 : </b> Murphy ML, Hultgren HN, Detre K, Thomsen J, Takaro TTreatment of chronic stable angina. A preliminary report of survival data of the randomized Veterans Administration cooperative study. <i>N Engl J Med 1977 Sep 22;297:621-7</i> [PMID 331107] </p> <p> <b>VA, 1984 : </b> Peduzzi P, Detre K, Gage AVeterans Administration Cooperative Study of medical versus surgical treatment for stable angina--progress report. Section 2. Design and baseline characteristics. <i>Prog Cardiovasc Dis 1985 Nov-Dec;28:219-28</i> [PMID 3903866] </p> <p> <b>VA, 1984 : </b> Detre K, Murphy M, Hammermeister KE, Sako Y, Meadows WRVeterans Administration Cooperative Study of medical versus surgical treatment for stable angina--progress report. Section 9. Effect of medical versus surgical treatment on resting left ventricular ejection fraction at five years. <i>Prog Cardiovasc Dis 1986 Jan-Feb;28:293-9</i> [PMID 3511513] </p> <p> <b>VA, 1984 : </b> Murphy ML, Meadows WR, Thomsen J, Hultgren HN, Takaro T, Fish R, Read RVeterans Administration Cooperative Study on medical versus surgical treatment for stable angina--progress report. Section 11. The effect of coronary artery bypass surgery on the incidence of myocardial infarction and hospitalization. <i>Prog Cardiovasc Dis 1986 Jan-Feb;28:309-17</i> [PMID 3511515] </p> <p> <b>ECSS (European), 1988 : </b> Varnauskas ETwelve-year follow-up of survival in the randomized European Coronary Surgery Study. <i>N Engl J Med 1988 Aug 11;319:332-7</i> [PMID 3260659] </p> <p> <b>ECSS (European), 1988 : </b> Long-term results of prospective randomised study of coronary artery bypass surgery in stable angina pectoris. European Coronary Surgery Study Group. <i>Lancet 1982 Nov 27;2:1173-80</i> [PMID 6128492] </p> <p> <b>ECSS (European), 1988 : </b> Coronary-artery bypass surgery in stable angina pectoris: Survival at two years. European Coronary Surgery Study Group. <i>Lancet 1979 Apr 28;1:889-93</i> [PMID 86665] </p> <p> <b>ECSS (European), 1988 : </b> Prospective randomised study of coronary artery bypass surgery in stable angina pectoris. Second interim report by the European Coronary Surgery Study Group. <i>Lancet 1980 Sep 6;2:491-5</i> [PMID 6105556] </p> <p> <b>ECSS (European), 1988 : </b> Prospective randomized study of coronary artery bypass surgery in stable angina pectoris: a progress report on survival. <i>Circulation 1982 Jun;65:67-71</i> [PMID 7044607] </p> <p> <b>CASS, 1983 : </b> Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Survival data. <i>Circulation 1983 Nov;68:939-50</i> [PMID 6137292] </p> <p> <b>CASS, 1983 : </b> Alderman EL, Bourassa MG, Cohen LS, Davis KB, Kaiser GG, Killip T, Mock MB, Pettinger M, Robertson TLTen-year follow-up of survival and myocardial infarction in the randomized Coronary Artery Surgery Study. <i>Circulation 1990 Nov;82:1629-46</i> [PMID 2225367] </p> <p> <b>CASS, 1983 : </b> Chaitman BR, Ryan TJ, Kronmal RA, Foster ED, Frommer PL, Killip TCoronary Artery Surgery Study (CASS): comparability of 10 year survival in randomized and randomizable patients. <i>J Am Coll Cardiol 1990 Nov;16:1071-8</i> [PMID 2229750] </p> <p> <b>CASS, 1983 : </b> Coronary artery surgery study (CASS): a randomized trial of coronary artery bypass surgery. Quality of life in patients randomly assigned to treatment groups. <i>Circulation 1983 Nov;68:951-60</i> [PMID 6137293] </p> <p> <b>CASS, 1983 : </b> Myocardial infarction and mortality in the coronary artery surgery study (CASS) randomized trial. <i>N Engl J Med 1984 Mar 22;310:750-8</i> [PMID 6608052] </p> <p> <b>CASS, 1983 : </b> Rogers WJ, Coggin CJ, Gersh BJ, Fisher LD, Myers WO, Oberman A, Sheffield LTTen-year follow-up of quality of life in patients randomized to receive medical therapy or coronary artery bypass graft surgery. The Coronary Artery Surgery Study (CASS) <i>Circulation 1990 Nov;82:1647-58</i> [PMID 1977531] </p> <p> <b>Texas, 1977 : </b> Mathur VS, Guinn GAProspective randomized study of the surgical therapy of stable angina. <i>Cardiovasc Clin 1977;8:131-44</i> [PMID 332367] </p> <p> <b>Oregon, 1979 : </b> Kloster FE, Kremkau EL, Ritzmann LW, Rahimtoola SH, Rösch J, Kanarek PHCoronary bypass for stable angina: a prospective randomized study. <i>N Engl J Med 1979 Jan 25;300:149-57</i> [PMID 310511] </p> <p> <b>New zealand 1, 1981 : </b> Norris RM, Agnew TM, Brandt PW, Graham KJ, Hill DG, Kerr AR, Lowe JB, Roche AH, Whitlock RM, Barratt-Boyes BGCoronary surgery after recurrent myocardial infarction: progress of a trial comparing surgical with nonsurgical management for asymptomatic patients with advanced coronary disease. <i>Circulation 1981 Apr;63:785-92</i> [PMID 7471334] </p> <p> <b>Leon (low dose), 2005 : </b> Leon MB, Kornowski R, Downey WE, Weisz G, Baim DS, Bonow RO, Hendel RC, Cohen DJ, Gervino E, Laham R, Lembo NJ, Moses JW, Kuntz REA blinded, randomized, placebo-controlled trial of percutaneous laser myocardial revascularization to improve angina symptoms in patients with severe coronary disease. <i>J Am Coll Cardiol 2005 Nov 15;46:1812-9</i> [PMID 16286164] </p> <p> <b>ISAR TEST 3 (BP), 2009 : </b> Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R, Schömig A, Kastrati A <i>Eur Heart J 2008 Aug;29:1975-82</i> [PMID 18550554] 10.1093/eurheartj/ehn253 </p> <p> <b>ISAR TEST 3 (BP), 2009 : </b> Byrne RA, Kufner S, Tiroch K, Massberg S, Laugwitz KL, Birkmeier A, Schulz S, Mehilli JRandomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results. <i>Heart 2009;95:1489-94</i> [PMID 19592388] </p> <p> <b>ISAR TEST 3 (PF), 2009 : </b> Mehilli J, Byrne RA, Wieczorek A, Iijima R, Schulz S, Bruskina O, Pache J, Wessely R, Schömig A, Kastrati A <i>Eur Heart J 2008 Aug;29:1975-82</i> [PMID 18550554] 10.1093/eurheartj/ehn253 </p> <p> <b>ZEST (vs PES), 2009 : </b> Seung-Jung Park Comparison of Sirolimus and Paclitaxel-Eluting Stents Versus Zotarolimus-Eluting Stents in Real World Practice: The ZEST Randomized Controlled Trial <i>ACC.09/i2, Orlando, FL, March 2009</i> [PMID ] </p> <p> <b>ZEST (vs PES), 2009 : </b> Park DW, Kim YH, Yun SC, Kang SJ, Lee SW, Lee CW, Park SW, Seong IW, Lee JH, Tahk SJ, Jeong MH, Jang Y, Cheong SS, Yang JY, Lim DS, Seung KB, Chae JK, Hur SH, Lee SG, Yoon J, Lee NH, Choi YJ, Kim HS, Kim KS, Kim HS, Hong TJ, Park HS, Park SJComparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial. <i>J Am Coll Cardiol 2010 Oct 5;56:1187-95</i> [PMID 20883925] 10.1016/j.jacc.2010.03.086 </p> <p> <b>STICH (ventricular reconstruction), 2009 : </b> Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O'Connor CM, Hill JA, Menicanti L, Sadowski Z, Desvigne-Nickens P, Rouleau JL, Lee KLCoronary bypass surgery with or without surgical ventricular reconstruction. <i>N Engl J Med 2009 Apr 23;360:1705-17</i> [PMID 19329820] 10.1056/NEJMoa0900559 </p> <p> <b>STICH (ventricular reconstruction), 2009 : </b> Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JLSTICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. <i>J Am Coll Cardiol 2010;56:490-8</i> [PMID 20670760] 10.1016/j.jacc.2009.11.102 </p> <p> <b>Thiele, 2009 : </b> Thiele H, Neumann-Schniedewind P, Jacobs S, Boudriot E, Walther T, Mohr FW, Schuler G, Falk VRandomized comparison of minimally invasive direct coronary artery bypass surgery versus sirolimus-eluting stenting in isolated proximal left anterior descending coronary artery stenosis. <i>J Am Coll Cardiol 2009 Jun 23;53:2324-31</i> [PMID 19539141] </p> <p> <b>ISAR-TEST-4 (biodegradable polymer), 2009 : </b> Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schömig A, Mehilli JRandomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. <i>Eur Heart J 2009 Aug 30;:</i> [PMID 19720642] </p> <p> <b>OCTOPUS (idem octostent), 2009 : </b> McLean DS, Sabatine MS, Guo W, McCabe CH, Cannon CP <i>J Thromb Thrombolysis 2007;24:85-91</i> [PMID 17323134] </p> <p> <b>OCTOPUS (idem octostent), 2009 : </b> Pinto DS, Kirtane AJ, Pride YB, Murphy SA, Sabatine MS, Cannon CP, Gibson CM <i>Am J Cardiol 2008 Feb 1;101:303-7</i> [PMID 18237589] </p> <p> <b>OCTOPUS (idem octostent), 2009 : </b> Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, Claeys MJ, Cools F, Hill KA, Skene AM, McCabe CH, Braunwald E <i>N Engl J Med 2005 Mar 24;352:1179-89</i> [PMID 15758000] </p> <p> <b>ARTS 2, 2010 : </b> Daemen J, Kuck KH, Macaya C, LeGrand V, Vrolix M, Carrie D, Sheiban I, Suttorp MJ, Vranckx P, Rademaker T, Goedhart D, Schuijer M, Wittebols K, Macours N, Stoll HP, Serruys PWMultivessel coronary revascularization in patients with and without diabetes mellitus: 3-year follow-up of the ARTS-II (Arterial Revascularization Therapies Study-Part II) trial. <i>J Am Coll Cardiol 2008;52:1957-67</i> [PMID 19055986] 10.1016/j.jacc.2008.09.010 </p> <p> <b>ARTS 2, 2010 : </b> Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Schuijer M, Rademaker T, Wittebols K, Stoll HP5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. <i>J Am Coll Cardiol 2010 Mar 16;55:1093-1101</i> [PMID 20171036] 10.1016/j.jacc.2009.11.049 </p> <p> <b>AWESOME, 2001 : </b> Morrison DA, Sethi G, Sacks J, Henderson W, Grover F, Sedlis S, Esposito R, Ramanathan K, Weiman D, Saucedo J, Antakli T, Paramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Barbiere C, Lewis DPercutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: a multicenter, randomized trial. Investigators of the Department of Veterans Affairs Cooperative Study #385, the Angina With Extremely Serious Operative Mortality Evaluation (AWESOME). <i>J Am Coll Cardiol 2001;38:143-9</i> [PMID 11451264] </p> <p> <b>AWESOME, 2001 : </b> Morrison DA, Sethi G, Sacks J, Grover F, Sedlis S, Esposito R, Ramanathan KB, Weiman D, Krucoff M, Duhaylongsod F, Raya T, Pett S, Vernon S, Birjiniuk V, Booth D, Robinson C, Talley JD, Antckli T, Murphy E, Floten H, Curcovic V, Lucke JC, Lewis D, BarbierA multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. The AWESOME (Veterans Affairs Cooperative Study #385, angina with extremely serious operative mortality evaluation) investigators from the Cooperative Studies Program of the Department of Veterans Affairs. <i>Control Clin Trials 1999;20:601-19</i> [PMID 10588300] </p> <p> <b>AWESOME, 2001 : </b> Morrison DA, Sethi G, Sacks J, Henderson WG, Grover F, Sedlis S, Esposito RPercutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. <i>J Am Coll Cardiol 2002;40:1951-4</i> [PMID 12475454] </p> <p> <b>AWESOME, 2001 : </b> Ramanathan KB, Weiman DS, Sacks J, Morrison DA, Sedlis S, Sethi G, Henderson WGPercutaneous intervention versus coronary bypass surgery for patients older than 70 years of age with high-risk unstable angina. <i>Ann Thorac Surg 2005;80:1340-6</i> [PMID 16181866] 10.1016/j.athoracsur.2005.03.057 </p> <p> <b>AWESOME, 2001 : </b> Rumsfeld JS, Magid DJ, Plomondon ME, Sacks J, Henderson W, Hlatky M, Sethi G, Morrison DAHealth-related quality of life after percutaneous coronary intervention versus coronary bypass surgery in high-risk patients with medically refractory ischemia. <i>J Am Coll Cardiol 2003;41:1732-8</i> [PMID 12767656] </p> <p> <b>AWESOME, 2001 : </b> Sedlis SP, Morrison DA, Lorin JD, Esposito R, Sethi G, Sacks J, Henderson W, Grover F, Ramanathan KB, Weiman D, Saucedo J, Antakli T, Paramesh V, Pett S, Vernon S, Birjiniuk V, Welt F, Krucoff M, Wolfe W, Lucke JC, Mediratta S, Booth D, Murphy E, Ward H, Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass: outcome of diabetic patients in the AWESOME randomized trial and registry. <i>J Am Coll Cardiol 2002;40:1555-66</i> [PMID 12427406] </p> <p> <b>AWESOME, 2001 : </b> Sedlis SP, Ramanathan KB, Morrison DA, Sethi G, Sacks J, Henderson WOutcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). <i>Am J Cardiol 2004;94:118-20</i> [PMID 15219521] 10.1016/j.amjcard.2004.03.041 </p> <p> <b>AWESOME, 2001 : </b> Stroupe KT, Morrison DA, Hlatky MA, Barnett PG, Cao L, Lyttle C, Hynes DM, Henderson WGCost-effectiveness of coronary artery bypass grafts versus percutaneous coronary intervention for revascularization of high-risk patients. <i>Circulation 2006;114:1251-7</i> [PMID 16966588] 10.1161/CIRCULATIONAHA.105.570838 </p> <p> <b>Myoprotect, 2004 : </b> Pohl T, Giehrl W, Reichart B, Kupatt C, Raake P, Paul S, Reichenspurner H, Steinbeck G, Boekstegers PRetroinfusion-supported stenting in high-risk patients for percutaneous intervention and bypass surgery: results of the prospective randomized myoprotect I study. <i>Catheter Cardiovasc Interv 2004;62:323-30</i> [PMID 15224298] 10.1002/ccd.20060 </p> <p> <b>RESOLUTE All comers, 2010 : </b> Serruys PW, Silber S, Garg S, van Geuns RJ, Richardt G, Buszman PE, Kelbæk H, van Boven AJ, Hofma SH, Linke A, Klauss V, Wijns W, Macaya C, Garot P, Dimario C, Manoharan G, Kornowski R, Ischinger T, Bartorelli A, Ronden J, Bressers M, Gobbens P, Negoita MComparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>N Engl J Med 2010 Jun 16;:</i> [PMID 20554978] 10.1056/NEJMoa1004130 </p> <p> <b>RESOLUTE All comers, 2010 : </b> Silber S, Windecker S, Vranckx P, Serruys PWUnrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial. <i>Lancet 2011 Apr 1;:</i> [PMID 21459430] 10.1016/S0140-6736(11)60395-4 </p> <p> <b>Boudriot, 2008 : </b> Boudriot E, Thiele H, Liebetrau C, Walther T. Pohl T, Boeckstegers P,Reichart B, Beier F, Mudra H, Kemkes BM, Gick M, Neumann FJ,Mohr FW, Schuler G.Randomized multicenter trial between PCI with sirolimus-eluting stent versus CABG for unprotected left main stenosis. <i>Transcatheter Cardiovascular Therapeutics; Washington, District of Columbia; 2008. </i> [PMID ] </p>